UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

WASHINGTON, D.C. 20549


FORM 10-Q

(Mark One)

☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934

For the quarterly period ended ~~September 30, 2022~~March 31, 2023

☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934

For the transition period from _____ to_____

Commission File Number 001-36533

MEDAVAIL HOLDINGS, INC.

(Exact name of registrant as specified in its charter)

Delaware

90-0772394

(State or other jurisdiction of incorporation or organization)

(I.R.S. Employer Identification Number)

4720 East Cotton Gin Loop, Suite 220, Phoenix, Arizona

85040

(Address of principal executive offices)

(Zip Code)

+1 (905) 812-0023

(Registrant’s telephone number, including area code)

Securities registered pursuant to Section 12(b) of the Act:

Title of each class

Trading Symbol(s)

Name of each exchange on which registered

Common Stock, par value $0.001 per share

MDVL

The Nasdaq Stock Market LLC

Indicate by check mark whether the registrant (1) has filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that the registrant was required to file such reports), and (2) has been subject to such filing requirements for the past 90 days. Yes ☒ No ☐

Indicate by check mark whether the registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule 405 of Regulation S-T (§232.405 of this chapter) during the preceding 12 months (or for such shorter period that the registrant was required to submit such files). Yes ☒ No ☐

Indicate by check mark whether the registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer, a smaller reporting company, or an emerging growth company. See the definitions of “large accelerated filer,” “accelerated filer,” “smaller reporting company,” and "emerging growth company" in Rule 12b-2 of the Exchange Act.


Large accelerated filer	☐	Accelerated filer	☐
Non-accelerated filer	☒	Smaller reporting company	☒
		Emerging growth company	☐

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐

Indicate by check mark whether the registrant is a shell company (as defined in Rule 12b-2 of the Exchange Act). Yes ☐ No ☒

As of ~~November 8, 2022,~~May 5, 2023, there were ~~80,045,696~~80,523,932 shares of the registrant’s common stock outstanding.

MedAvail Holdings, Inc.

Form 10-Q

For the Three ~~and Nine~~ Months Ended ~~September 30, 2022~~March 31, 2023

TABLE OF CONTENTS


		Page

PART I
Item 1.	Financial Statements (Unaudited)	5
	Condensed Consolidated Balance Sheets	5
	Condensed Consolidated Statements of Operations and Comprehensive Loss	67
	Condensed Consolidated Statements of ~~Shareholders'~~Stockholders' Equity	78
	Condensed Consolidated Statements of Cash Flows	89
	Notes to Condensed Consolidated Financial Statements	1011
Item 2.	Management's Discussion and Analysis of Financial Condition and Results of Operations	2623
Item 3.	Quantitative and Qualitative Disclosures about Market Risk	3730
Item 4.	Controls and Procedures	3730

PART II
Item 1.	Legal Proceedings	3831
Item 1A.	Risk Factors	3831
Item 2.	Unregistered Sales of Equity Securities and Use of Proceeds	3932
Item 3.	Defaults Upon Senior Securities	3932
Item 4.	Mine Safety Disclosures	3932
Item 5.	Other Information	3932
Item 6.	Exhibits	4033

Signatures		4134

SPECIAL NOTE REGARDING FORWARD-LOOKING STATEMENTS

This Quarterly Report on Form 10-Q contains forward-looking statements within the meaning of Section 27A of the Securities Act of 1933, as amended, or the Securities Act, and Section 21E of the Securities Exchange Act of 1934, as amended, or the Exchange Act, concerning our business, operations and financial performance and condition, as well as our plans, objectives and expectations for our business, operations and financial performance and condition. Any statements contained herein ~~that are~~ not statements of historical facts may be deemed to be forward-looking statements. In some cases, you can identify forward-looking statements by terminology such as “anticipate,” “assume,” “believe,” “contemplate,” “continue,” “could,” “due,” “estimate,” “expect,” “goal,” “intend,” “may,” “objective,” “plan,” “predict,” “potential,” “positioned,” “seek,” “should,” “target,” “will,” “would” and other similar expressions that are predictions of or indicate future events and future trends, or the negative of these terms or other comparable terminology.

These forward-looking statements include, but are not limited to, statements about:

•the impact of our decision to exit our pharmacy services business and related asset sales and reductions in force;

•our plans to modify our current products, or develop new products;

•the expected growth of our business and organization;

•our expectations regarding the size of our sales organization and expansion of our sales and marketing efforts;

•our ability to retain and recruit key personnel, including the continued development of a sales and marketing infrastructure;

•our ability to obtain and maintain intellectual property protection for our products;

•our ability to expand our business into new geographic markets;

•our compliance with extensive Nasdaq requirements and government laws, rules and regulations both in the United States and internationally;

•our estimates of expenses, ongoing losses, future revenue, capital requirements and our need for, or ability to obtain, additional financing;

•our ability to identify and develop new and planned products and/or acquire new products;

•~~the expectations regarding the impact of the COVID-19 pandemic on our business;~~

•existing regulations and regulatory developments in the United States, Canada and other jurisdictions;

•the impact of laws and regulations;

•our financial performance;

•the period over which we estimate our existing cash, cash equivalents and available-for-sale investments will be sufficient to fund our future operating expenses and capital expenditure requirements;

•our anticipated use of our existing resources;

•developments and projections relating to our competitors or our industry; and

•the impact of general market and macroeconomic conditions, the effect of inflationary pressure, including ~~inflation~~any impact of adverse developments affecting the financial services industry, such as those based on liquidity constraints or concerns and events including the outbreak of war in Ukraine,

on our business.

We believe that it is important to communicate our future expectations to our investors. However, there may be events in the future that we are not able to accurately predict or control and that may cause our actual results to differ materially from the expectations we describe in our forward-looking statements. These forward-looking statements are based on management’s current expectations, estimates, forecasts and projections about our business and the industry in which we ~~operate and~~operate. These forward-looking statements are management’s beliefs and assumptions and are not guarantees of future performance or development and involve known and unknown risks, uncertainties and other factors that are in some cases beyond our control. As a result, any or all of our forward-looking statements in this Quarterly Report on Form 10-Q may turn out to be inaccurate. Factors that may cause actual results to differ materially from current expectations include, among other things, those listed under “Risk Factors” and elsewhere in this Quarterly Report on Form ~~10-Q.~~10-Q and in our Annual Report on Form 10-K filed

with the Securities and Exchange Commission, or SEC. Potential investors are urged to consider these factors carefully in evaluating the forward-looking statements. These forward-looking statements speak only as of the date of this Quarterly Report on Form 10-Q. We assume no obligation to update or revise these forward-looking statements for any reason, even if new information becomes available in the future.

You should not rely upon forward-looking statements as predictions of future events. Although we believe that the expectations reflected in the forward-looking statements are reasonable, we cannot guarantee that the future results, levels of activity, performance or events and circumstances reflected in the forward-looking statements will be achieved or occur. We undertake no obligation to update publicly any forward-looking statements for any reason after the date of this Quarterly Report on Form 10-Q to conform these statements to actual results or to changes in our expectations.

You should read this Quarterly Report on Form 10-Q and the documents that we reference in this Quarterly Report on Form 10-Q and have filed with the SEC as exhibits to ~~the~~this Quarterly Report on Form 10-Q with the understanding that our actual future results, levels of activity, performance and events and circumstances may be materially different from what we expect.

PART I

Item 1. Financial Statements

MEDAVAIL HOLDINGS, INC.

Condensed Consolidated Balance Sheets

(Unaudited)

(in ~~thousands, except share amounts)~~thousands)

September 30, December 31,
2022 2021
Assets
Current assets:
Cash and cash equivalents $ 27,196 $ 19,689
Restricted cash 676 400
Accounts receivable (net of allowance for doubtful accounts of $186 thousand for September 30, 2022, $66 thousand for December 31, 2021) 2,262 1,189
Inventories 6,401 3,916
Prepaid expenses and other current assets 2,863 2,191
Total current assets 39,398 27,385
Property, plant and equipment, net 6,370 5,692
Intangible assets, net 1,580 2,300
Right-of-use assets 2,270 2,538
Other assets 233 228
Total assets $ 49,851 $ 38,143
Liabilities and Stockholders' Equity
Current liabilities:
Accounts payable $ 2,006 $ 2,477
Accrued liabilities 1,383 1,530
Accrued payroll and benefits 2,869 2,733
Deferred revenue 70 83
Current portion of lease obligations 728 682
Total current liabilities 7,056 7,505
Long-term debt, net 9,751 9,538
Long-term portion of lease obligations 1,738 2,027
Total liabilities 18,545 19,070
Commitments and contingencies
Stockholders' equity:
Common shares ($0.001 par value, 300,000,000 shares authorized, 80,045,696 and 32,902,048 shares issued and outstanding at September 30, 2022 and December 31, 2021, respectively) 80 33
Warrants 11,148 1,373
Additional paid-in-capital 255,642 216,685
Accumulated other comprehensive loss (6,928) (6,928)
Accumulated deficit (228,636) (192,090)
Total stockholders' equity 31,306 19,073
Total liabilities and stockholders' equity $ 49,851 $ 38,143


	March 31, 2023		December 31, 2022
Assets
Current assets:
Cash and cash equivalents	$	18,796	$	11,444
Restricted cash	676		676
Accounts receivable	207		404
Inventories	8,701		3,994
Prepaid expenses and other current assets	2,072		2,569

Current assets from discontinued operations	2,079		4,842
Total current assets	32,531		23,929
Property, plant and equipment, net	789		5,261
Intangible assets, net	425		451
Right-of-use assets	773		624
Other assets	30		30

Long-term assets from discontinued operations	1,166		2,837
Total assets	$	35,714	$	33,132

The accompanying notes are an integral part of these unaudited condensed consolidated financial statements.

MEDAVAIL HOLDINGS, INC.

Condensed Consolidated ~~Statements of Operations and Comprehensive Loss~~Balance Sheets (Continued)

(Unaudited)

(in thousands, except share and ~~per-share~~per share amounts)


	March 31, 2023		December 31, 2022
Liabilities and Stockholders' Equity
Current liabilities:
Accounts payable	$	898	$	818
Accrued liabilities	592		552
Accrued payroll and benefits	1,240		1,379
Deferred revenue	275		152
Current portion of lease obligations	244		246

Current liabilities from discontinued operations	1,885		2,794
Total current liabilities	5,134		5,941
Warrant liabilities	23,378		—
Long-term debt, net	1,428		4,798
Long-term portion of lease obligations	590		441
Long-term liabilities from discontinued operations	1,015		1,128
Total liabilities	31,545		12,308
Commitments and contingencies (Note 10)
Stockholders' equity:
Common shares ($0.001 par value, 300,000,000 shares authorized, 80,480,641 and 80,169,719 shares issued and outstanding at March 31, 2023 and December 31, 2022, respectively)	81		81
Warrants	11,205		11,148
Additional paid-in-capital	256,847		256,229
Accumulated other comprehensive loss	(6,928)		(6,928)
Accumulated deficit	(257,036)		(239,706)
Total stockholders' equity	4,169		20,824
Total liabilities and stockholders' equity	$	35,714	$	33,132

Three Months Ended September 30, Nine Months Ended September 30,
2022 2021 2022 2021
Revenue:
Pharmacy and hardware revenue $ 11,266 $ 5,659 $ 31,210 $ 14,165
Service revenue 195 133 549 684
Total revenue 11,461 5,792 31,759 14,849
Cost of products sold and services:
Pharmacy and hardware cost of products sold 10,113 5,539 28,827 13,744
Service costs 56 67 221 426
Total cost of products sold and services 10,169 5,606 29,048 14,170
Operating expense:
Pharmacy operations 4,392 3,750 11,970 9,428
General and administrative 6,087 5,320 18,729 16,733
Selling and marketing 2,126 1,909 6,738 5,056
Research and development 178 232 952 601
Total operating expense 12,783 11,211 38,389 31,818
Operating loss (11,491) (11,025) (35,678) (31,139)
Other gain (loss), net — 7 — 206
Interest income — 7 1 74
Interest expense (315) (260) (845) (328)
Loss before income taxes (11,806) (11,271) (36,522) (31,187)
Income tax expense — (2) (24) (2)
Net loss and comprehensive loss $ (11,806) $ (11,273) $ (36,546) $ (31,189)
Net loss per share - basic and diluted $ (0.15) $ (0.34) $ (0.60) $ (0.96)
Weighted average shares outstanding - basic and diluted 80,045,995 32,750,831 60,947,511 32,580,199

The accompanying notes are an integral part of these unaudited condensed consolidated financial statements.

MEDAVAIL HOLDINGS, INC.

Condensed Consolidated Statements of ~~Shareholders' Equity~~Operations and Comprehensive Loss

(Unaudited)

(in thousands, except ~~per~~ share and per-share amounts)

Common Shares
Preferred Shares (1)
Warrants Additional Paid-in-Capital Accumulated Deficit Accumulated Other Comprehensive Loss Total Stockholders' Equity
Shares Amount Shares Amount
Balance at June 30, 2022 70,609,972 $ 71 — $ — $ 8,876 $ 247,598 $ (216,830) $ (6,928) $ 32,787
Net loss — — — — — — (11,806) — (11,806)
Issuance of common shares 9,411,765 9 — — — 9,751 — — 9,760
Issuance of warrants — — — — 2,272 (2,272) — — —
Shares issued for vested restricted stock units 23,959 — — — — — — — —
Share-based compensation — — — — — 565 — — 565
Balance at September 30, 2022 80,045,696 $ 80 — $ — $ 11,148 $ 255,642 $ (228,636) $ (6,928) $ 31,306
Balance at December 31, 2021 32,902,048 $ 33 — — $ 1,373 $ 216,685 $ (192,090) $ (6,928) $ 19,073
Net loss — — — — — — (36,546) — (36,546)
Issuance of common shares 47,058,820 47 — — — 46,914 — — 46,961
Issuance of warrants — — — — 9,775 (9,775) — — —
Shares issued for vested restricted stock units 30,833 — — — — — — — —
Issuance of common shares under employee stock purchase plan 53,995 — — — — 77 — — 77
Share-based compensation — — — — — 1,741 — — 1,741
Balance at September 30, 2022 80,045,696 $ 80 — $ — $ 11,148 $ 255,642 $ (228,636) $ (6,928) $ 31,306
Balance at June 30, 2021 32,583,734 $ 33 — $ — $ 1,485 $ 215,700 $ (168,191) $ (6,928) $ 42,099
Net loss — — — — — — (11,273) — (11,273)
Exercise of warrants 171,191 — — — (112) 139 — — 27
Share-based compensation — — — — — 365 — — 365
Balance at September 30, 2021 32,754,925 $ 33 — $ — $ 1,373 $ 216,204 $ (179,464) $ (6,928) $ 31,218
Balance at December 31, 2020 31,816,020 32 — — 2,614 213,624 (148,275) (6,928) 61,067
Net loss — — — — — — (31,189) — (31,189)
Exercise of options 144,101 — — — — 241 — — 241
Exercise of warrants 794,804 1 — — (1,241) 1,391 — — 151
Share-based compensation — — — — — 948 — — 948
Balance at September 30, 2021 32,754,925 $ 33 — $ — $ 1,373 $ 216,204 $ (179,464) $ (6,928) $ 31,218

~~(1)~~ ~~$0.001 par value, 10,000,000 shares authorized for all periods presented.~~


	Three Months Ended March 31,
		2023		2022
Revenue:
Hardware and subscription revenue		$	304	$	165
Service revenue		316		100
Total revenue		620		265
Cost of products sold and services:
Hardware cost of products sold		245		81
Service costs		118		50
Total cost of products sold and services		363		131
Other operating expenses:

General and administrative		4,960		5,190
Selling and marketing		132		100
Research and development		176		258
Total operating expense		5,268		5,548
Operating loss		(5,011)		(5,414)

Loss on issuance of warrants		(10,424)		—
Gain from change in fair value of warrant liabilities		3,045		—
Interest income		1		1
Interest expense		(169)		(251)


Net loss and comprehensive loss from continued operations		(12,558)		(5,664)
Discontinued operations:
Loss from discontinued operations		(4,772)		(7,358)


Net loss		$	(17,330)	$	(13,022)

Basic and diluted net loss per share:
Loss from continued operations		$	(0.16)	$	(0.17)
Loss from discontinued operations		$	(0.06)	$	(0.22)
Weighted average shares outstanding - basic and diluted		80,270,494		32,921,969

The accompanying notes are an integral part of these unaudited condensed consolidated financial statements.

MEDAVAIL HOLDINGS, INC.

Condensed Consolidated Statements of ~~Cash Flows~~Stockholders' Equity

(Unaudited)

(in ~~thousands)~~thousands, except share amounts)

Nine Months Ended September 30,
2022 2021
Cash flows from operating activities:
Net loss $ (36,546) $ (31,189)
Adjustments to reconcile net loss to net cash used in operating activities:
Depreciation of property, plant, and equipment 891 928
Amortization of intangible and leased assets 2,141 877
Bad debt and other non-cash receivables adjustments 120 47
Term loan discount amortization and interest accretion on debt 213 —
Impairment of lease asset (27) —
Share-based compensation expense 1,741 948
PPP loan forgiveness gain — (161)
Changes in operating assets and liabilities:
Accounts receivable (1,193) 398
Inventory (3,354) (2,511)
Prepaid expenses and other current assets (672) 772
Accounts payable, accrued expenses and other liabilities (137) 2,180
Deferred revenue (13) 42
Operating lease liability due to cash payments (447) (505)
Net cash used in operating activities (37,283) (28,174)
Cash flows from investing activities:
Purchase of property, plant and equipment (804) (680)
Payment of security deposits (5) (45)
Purchase of intangible and other assets (1,088) (1,544)
Net cash used in investing activities (1,897) (2,269)
Cash flows from financing activities:
Proceeds from issuance of common shares, net 46,961 —
Proceeds from issuance of common shares upon exercise of options and warrants — 392
Proceeds from issuance of common shares upon exercise of employee stock purchase plan 77 —
Proceeds from debt — 10,000
Payment of debt issuance costs — (624)
Repayment of debt — (1,000)
Payments on finance lease obligations (75) (46)
Net cash provided by financing activities 46,963 8,722
Net increase (decrease) in cash, cash equivalents and restricted cash 7,783 (21,721)
Cash, cash equivalents and restricted cash at beginning of period 20,089 57,996
Cash, cash equivalents and restricted cash at end of period $ 27,872 $ 36,275


	Common Shares			Warrants			Additional Paid-in-Capital			Accumulated Deficit			Accumulated Other Comprehensive Loss			Total Stockholders' Equity
	Shares	Amount







Balance at December 31, 2022	80,169,719	$	81		$	11,148		$	256,229		$	(239,706)		$	(6,928)		$	20,824
Net loss	—	—			—			—			(17,330)			—			(17,330)
Shares issued for vested RSUs	310,922	—			—			—			—			—			—

Warrants issued	—	—			57			—			—			—			57
Share-based compensation	—	—			—			618			—			—			618
Balance at March 31, 2023	80,480,641	$	81		$	11,205		$	256,847		$	(257,036)		$	(6,928)		$	4,169
















Balance at December 31, 2021	32,902,048	$	33		$	1,373		$	216,685		$	(192,090)		$	(6,928)		$	19,073
Net loss	—	—			—			—			(13,022)			—			(13,022)
Shares issued for vested restricted stock units	6,874	—			—			—			—			—			—
Share-based compensation	—	—			—			564			—			—			564
Balance at March 31, 2022	32,908,922	$	33		$	1,373		$	217,249		$	(205,112)		$	(6,928)		$	6,615

The accompanying notes are an integral part of these unaudited condensed consolidated financial statements.

MEDAVAIL HOLDINGS, INC.

Condensed Consolidated ~~Statement~~Statements of Cash Flows

(Unaudited)

(in thousands)

Nine Months Ended September 30,
2022 2021
Supplemental cash flow information:
Cash paid for interest $ 603 $ 125
Supplemental noncash investing and financing activities:
Inventory transferred to property, plant and equipment $ 869 $ 1,075
Property, plant and equipment transferred to intangible assets $ — $ 46
Purchase of property, plant and equipment in accounts payable $ 21 $ 56
Purchase of intangible assets in accounts payable $ — $ 398
Fair value of warrants issued upon closing of private placement $ 9,775 $ —
Lease liabilities arising from obtaining right of use assets:
Operating leases $ 206 $ 2,177
Finance leases $ 73 $ 97


	Three Months Ended March 31,
	2023		2022
Cash flows from operating activities:
Net loss	$	(17,330)	$	(13,022)
Adjustments to reconcile net loss to net cash used in operating activities:
Depreciation of property, plant, and equipment	671		286
Amortization of intangible and leased assets	213		312
Loss on disposal of net assets from discontinued operations	818		30
Loss on issuance of warrants	10,424		—
Gain from change in fair value of warrants	(3,045)		—

Term loan discount amortization and interest accretion on debt	67		70
Share-based compensation expense	618		564
Changes in operating assets and liabilities:
Accounts receivable	(103)		(589)
Inventory	2,887		(1,601)
Prepaid expenses and other current assets	518		(914)
Accounts payable	(472)		935
Accrued liabilities	504		125
Accrued payroll and benefits	(946)		645
Deferred revenue	123		24
Operating lease liability due to cash payments	(157)		(129)
Net cash used in operating activities	(5,210)		(13,264)
Cash flows from investing activities:
Purchase of property, plant and equipment	(17)		(343)
Payment of security deposits	—		(5)
Purchase of intangible assets and other assets	—		(504)
Net cash used in investing activities	(17)		(852)
Cash flows from financing activities:
Proceeds from issuance of warrants in private placement	15,999		—
Payment of debt issuance costs	(380)		—
Repayment of debt	(3,000)		—
Payments on finance lease obligations	(40)		(23)
Net cash provided by (used in) financing activities	12,579		(23)
Net increase (decrease) in cash, cash equivalents and restricted cash	7,352		(14,139)
Cash, cash equivalents and restricted cash at beginning of period	12,120		20,089
Cash, cash equivalents and restricted cash at end of period	$	19,472	$	5,950

The accompanying notes are an integral part of these unaudited condensed consolidated financial statements.

MEDAVAIL HOLDINGS, INC.

Condensed Consolidated Statements of Cash Flows (Continued)

(Unaudited)

(in thousands)


	Three Months Ended March 31,
	2023		2022
Supplemental cash flow information:
Cash paid for interest	$	178	$	184
Supplemental noncash investing and financing activities:
Inventory transferred to property, plant and equipment	$	—	$	429
MedCenter equipment from discontinued operations transferred to inventory for continuing operations (See Note 7)	$	4,651	$	—
Purchase of property, plant and equipment in accounts payable	$	—	$	122
Purchase of intangible assets in accounts payable	$	—	$	326

Lease liabilities arising from obtaining right of use assets:
Operating leases	$	—	$	205
Finance leases	$	231	$	73

The accompanying notes are an integral part of these unaudited condensed consolidated financial statements.

MEDAVAIL HOLDINGS, INC.

Notes to Condensed Consolidated Financial Statements

(Unaudited)

NOTE 1 - NATURE OF OPERATIONS

MedAvail Holdings, Inc., or MedAvail, or the Company, a Delaware corporation, ~~formerly known as MYOS RENS Technology,~~ is a pharmacy technology and services company that has developed and commercialized an innovative self-service pharmacy, mobile application, and kiosk. The Company’s principal technology and product is the MedCenter, a pharmacist controlled, customer-interactive, prescription dispensing system akin to a “pharmacy in a box” or prescription-dispensing ATM. The MedCenter ~~facilitates~~also has the ability to facilitate live pharmacist counseling via two-way audio-video communication with the ability to dispense prescription medicines under pharmacist control.

Exit of Pharmacy Services and SpotRx

On January 19, 2023, the Company announced a plan to exit the pharmacy services business to focus on its pharmacy technology business. In connection with its decision to exit the pharmacy services business, the Company initiated a reduction in force, in which employees of the pharmacy services business, representing at that time approximately 75% of the Company’s full-time employees, were terminated, effective January 18, 2023. The Company ~~also operates~~initiated the reduction in force to preserve capital and use its limited resources to pursue the pharmacy technology business.

On January 20, 2023, the Company entered into an Asset Purchase and Sale Agreement, as amended, with German Dobson CVS, L.L.C., Garfield Beach CVS, L.L.C., Longs Drug Stores California, L.L.C., Woodward Detroit CVS, L.L.C. and Holiday CVS, L.L.C., or CVS, pursuant to which the Company agreed to sell to CVS certain assets, including pharmacy records, and inventory from SpotRx orpharmacies located in Tucson and Phoenix, Arizona; Buena Park, Laguna Hills and San Fernando, California; Southfield, Michigan; and in Orlando and Tampa, Florida. The transaction closed on February 9, 2023, for a final purchase price of $2.9 million (subject to $0.1 million in fees and a $0.2 million indemnification holdback). Upon closing, the ~~Pharmacy, a full-service retail~~ pharmacy ~~utilizing~~records and inventory purchased by CVS were transferred from the SpotRx pharmacies to nearby CVS pharmacy locations.

For the year ended December 31, 2022, the pharmacy services business comprised approximately 97% of the Company’s ~~automated~~total revenues. As of December 31, 2022, inventory from SpotRx pharmacies comprised approximately $3.0 million, or 9%, of total consolidated assets. Pharmacy service business assets that were not sold to CVS have been or are expected to be primarily reabsorbed or settled, or to a lesser extent, sold or abandoned. As of March 31, 2023, the Company substantially completed its exit from the pharmacy ~~technology.~~services business.

The accounting requirements for reporting the pharmacy services business as a discontinued operation were met during the three months ended March 31, 2023. Accordingly, the condensed consolidated financial statements and notes to the consolidated condensed financial statements reflect the results of the pharmacy service business as a discontinued operation for the periods presented. See to Note 13 for additional information.

NOTE 2 - ~~GOING CONCERN~~LIQUIDITY

The condensed consolidated financial statements for the three months ended March 31, 2023 and the year ended December 31, 2022, were prepared on the basis of a going concern which contemplates that the Company will be able to realize assets and discharge liabilities in the normal course of business.

On March 9, 2023, the Company entered into a Securities Purchase Agreement, or private placement (the “Offering”), of securities with certain institutional investors, or the Investors. Upon close of the transaction the Company received gross proceeds from the Offering of approximately $16.0 million, before deducting offering expenses. The Company intends to use the net proceeds from this offering to fund one-time costs associated with restructuring, repay outstanding debt, and finance its growth initiatives related to its MedCenter technology business. Pursuant to the offering, the Company agreed to issue pre-funded warrants to purchase up to an aggregate of 49,813,198 shares of common stock at an exercise price of $0.001 per share, or Pre-Funded Warrants, and agreed to issue Series A warrants to purchase up to an aggregate of 49,813,198 shares of common stock at an exercise price of $0.38544 per share, or Series A Warrants, to be issued following stockholder approval of the issuance of the Series A Warrants.

As of March 31, 2023, the Company had $19.5 million in cash and cash equivalents, including restricted cash, and an accumulated deficit of $257.0 million. Furthermore, net cash used in operating activities for the three months ended March 31, 2023 and 2022 was $5.2 million and $13.3 million, respectively. Since inception through March 31, 2023, the Company has continually incurred losses from its operations, which have been financed primarily by net cash proceeds from sales of common stock and warrants in private placements, sales of redeemable preferred stock and debt.

Relevant accounting standards require that management make a determination as to whether or not substantial doubt exists as to the ~~Company's~~Company’s ability to continue as a going concern. If substantial doubt does exist ~~then~~ management should determine if there are plans in place which alleviate that doubt. ~~Since inception~~As of December 31, 2021, and through ~~September 30, 2022,~~ the Company has continually incurred losses from operations which have been financed primarily by net cash proceeds from the sale of stock from private placements, the sale of redeemable preferred stock and debt. Net cash used in operating activities for nine months ended September 30, 2022, ~~and 2021 was $37.3 million and $28.2 million, respectively. As of September 30, 2022,~~ the Company had ~~$27.2 million in cash and cash equivalents and an accumulated deficit of $228.6 million.~~

In April 2022, the Company completed a private placement, pursuant to which the Company received $40.0 million in gross proceeds, with an additional $10.0 million in gross proceeds received upon the second close that occurred on July 1, 2022, before deducting placement agent commissions and other offering expenses totaling $3.0 million. Additionally, the private placement included warrants, some of which may be callable at the Company’s option beginning on each of the 12 month and 24 month anniversaries of the warrant issuance dates and subject to the satisfaction of certain pricing conditions relating to the trading of the Company’s shares. See Note 11 for further information regarding the private placement warrants.

~~Due to the Company’s significant and ongoing cash requirements to fund operations, management determined that there is~~identified substantial doubt as to the Company’s ability to continue as a going concern. ~~The Company added liquidity resources in 2021 through a senior secured term loan facility with Silicon Valley Bank as described in Note 8, pursuant to which~~During the ~~Company borrowed $10.0 million in aggregate initial term loans. Additionally, as referenced above,~~first quarter of 2023, the Company raised ~~$40.0 million and $10.0 million~~capital in ~~gross proceeds through~~ a private placement ~~that closed in April 2022~~ and ~~July 2022, respectively. There can be no assurance~~reduced operating costs by exiting its pharmacy services business. As a result, after considering the Company's ongoing cash requirements to fund operations, management determined that the ~~steps management is taking will be successful. If~~Company has sufficient financial resources to continue operations through the ~~Company is unable to raise additional capital in sufficient amounts or on acceptable terms, the Company may have to significantly reduce operations or delay, scale back or discontinue development~~date of this report and ~~expansion plans. The condensed consolidated financial statements do not include any adjustments that might result~~one year from the ~~outcome~~date of ~~this uncertainty. The~~the financial statement issuance date, with no substantial doubt as to the Company’s ~~ultimate success will largely depend on continued development and deployment of MedCenter kiosks and SpotRx pharmacy operations and the~~ ability to ~~raise significant additional funding.~~continue as a going concern.

NOTE 3 - BASIS OF PRESENTATION

The accompanying unaudited condensed consolidated financial statements as of ~~September 30, 2022~~March 31, 2023, and for the three ~~and nine~~ months ended ~~September 30,~~March 31, 2023 and 2022 ~~and 2021~~ have been prepared in accordance with generally accepted accounting principles in the United States of America ("GAAP") for unaudited interim financial information, and in accordance with the rules of the Securities and Exchange Commission ("SEC") applicable to interim reports of companies filing as a smaller reporting company. Accordingly, the unaudited interim condensed consolidated financial statements do not include all of the information and footnotes required by GAAP for audited financial statements. The condensed consolidated balance sheet as of December 31, ~~2021~~2022 was derived from the Company's audited consolidated financial statements but does not include all disclosures required by GAAP for audited financial statements.

The preparation of financial statements in accordance with GAAP requires management to use judgment in the application of accounting policies, including making estimates and assumptions. Actual results could differ from those estimates. The Company's critical accounting policies are those that are both most important to its financial condition and results of operations and require the most difficult, subjective or complex judgments on the part of management in their application, often as a result of the need to make estimates about the effect of matters that are inherently uncertain. The Company is not aware of any events or circumstances which would require update to its estimates or judgements as disclosed in the Company's Annual Report on Form 10-K for the year ended December 31, 2022.

In the opinion of the Company's management, the interim information includes all adjustments, which include normal recurring adjustments, necessary for a fair statement of the results for the interim periods. The footnote disclosures related to the interim financial information included herein are also unaudited. Such financial information should be read in conjunction with the consolidated financial statements and related notes thereto for the year ended December 31, ~~2021~~2022 included in the Company's Annual Report on Form 10-K for the year ended December 31, ~~2021,~~2022, which was filed with the Securities and Exchange Commission, or SEC on ~~March 29, 2022, or the 2021 Form 10-K.~~

The preparation of financial statements in accordance with US GAAP requires management to use judgment in the application of accounting policies, including making estimates and assumptions. Actual results could differ from those estimates. Estimates are used in accounting for,

among other things, revenue recognition, contract loss accruals, excess, slow-moving and obsolete inventories, product warranty accruals, loss accruals on service agreements, share-based compensation expense, allowance for doubtful accounts, depreciation and amortization and in-process research and development intangible assets, and impairment of long-lived assets and contingencies. Estimates and assumptions are reviewed periodically, and the effects of revisions are reflected in the condensed consolidated financial statements in the period they are deemed to be necessary.

~~Risks and uncertainties relating to COVID-19~~

The Company bases its estimates on the information available at the time, its experiences and various other assumptions believed to be reasonable under the circumstances including estimates of the impact of COVID-19. The extent to which COVID-19 impacts the Company’s business and financial results will depend on numerous evolving factors, including but not limited to, the severity and duration of COVID-19, the extent to which it will impact the Company's clinic customers, employees, suppliers, vendors, and business partners. The Company assessed certain accounting matters that require consideration of estimates and assumptions in context with the information reasonably available to the Company and the unknown future impacts of COVID-19 as of September 30, 2022 and through the date of this report. The accounting matters assessed included, but were not limited to, the Company’s recoverability of, intangible and other long-lived assets including operating lease right-of-use assets. The Company’s future assessment of the magnitude and duration of COVID-19, as well as other factors, could result in material impacts to the Company’s condensed consolidated financial statements in future reporting periods. Adjustments may be made in subsequent periods to reflect more current estimates and assumptions about matters that are inherently uncertain. Actual results could differ from these estimates and any such differences may be material to the Company’s financial statements.April 14, 2023.

Principles of consolidation

The unaudited condensed consolidated financial statements include the accounts of all entities controlled by MedAvail Holdings, Inc., which are referred to as subsidiaries. The Company's subsidiaries include MedAvail Technologies, Inc., MedAvail Technologies (US), Inc., MedAvail Pharmacy, Inc., and MedAvail, Inc. The Company has no interests in variable interest entities of which the Company is the primary beneficiary. All intercompany balances and transactions have been eliminated.

~~Reclassifications~~

~~During~~As noted in Note 2, as of March 31, 2023, the ~~fourth quarter of 2021, management reclassified certain operating expenses to reflect~~Company substantially completed its exit from the ~~costs attributable to~~ pharmacy operations. Specifically, certain costs were reclassified from general and administrative expenses, to pharmacy operations expenses and selling and marketing expenses. This reclassification had no impact onservices business. As a result, the Company has reported the operating results of its pharmacy services business in the loss ~~subtotal within~~from discontinued operations line in the condensed consolidated statements of operations for all periods presented. In addition, related assets and ~~comprehensive loss. The effect~~liabilities were reported as assets of ~~the reclassifications within~~discontinued operations and liabilities of discontinued operations in the condensed consolidated ~~statement~~balance sheets for all periods presented. Unless otherwise noted, the discussion within these notes to the consolidated financial statements relates to continuing operations comprised of ~~operations and comprehensive loss~~the pharmacy technology business. See Note 13 for ~~2021 are as follows (in thousands):~~

Three Months Ended September 30, 2021
Current presentation As previously reported Change
Pharmacy operations $ 3,750 $ 2,395 $ 1,355
General and administrative 5,320 6,805 (1,485)
Selling and marketing 1,909 1,779 130
$ 10,979 $ 10,979 $ —
additional information on discontinued operations.

Nine Months Ended September 30, 2021
Current presentation As previously reported Change
Pharmacy operations $ 9,428 $ 6,619 $ 2,809
General and administrative 16,733 19,941 (3,208)
Selling and marketing 5,056 4,657 399
$ 31,217 $ 31,217 $ —

NOTE 4 - RECENT ACCOUNTING PRONOUNCEMENTS

Recently Issued Accounting Standards Not Yet Adopted

Fair Value Measurement of ~~Credit Losses on Financial Statements~~

In June 2016, the FASB issued ASU No. 2016-13, “Financial Instruments-Credit Losses (Topic 326)”- Measurement of Credit Losses on Financial Instruments”, (“ASU 2016-13”), supplemented by ASU 2018-19, “Codification ImprovementsEquity Securities Subject to Topic 326, Financial Instruments – Credit Losses”, (“ASU 2018-19”). The new standard requires entities to measure all expected credit losses for financial assets held at the reporting date based on historical experience, current conditions, and reasonable and supportable forecasts. ASU 2016-13 became effective for Public Business Entities who are SEC filers for fiscal years beginning after December 15, 2019, other than smaller reporting companies, all other public business entities and private companies, with early adoption permitted. ASU No. 2016-13 will be effective beginning in the first quarter of the Company's fiscal year 2023. The Company is currently evaluating the impact that this new guidance will have on its consolidated financial statements and related disclosures.Contractual Sale Restrictions

In June 2022, the FASB issued ASU No. 2022-03, “Fair Value Measurement (Topic 820):”- Fair Value Measurement of Equity Securities Subject to Contractual Sale Restrictions”, (“or ASU ~~2022-03”).~~2022-03. The amendments in this update clarify the guidance in Topic 820. ASU 2022-03 becomes effective for Public Business Entities who are SEC filers for fiscal years beginning after December 15, 2023, and interim periods within those fiscal years. Early adoption is permitted. ASU No. 2022-03 will be effective beginning in the first quarter of the Company's fiscal year 2024. The Company has not yet completed its evaluation of the impact of this new guidance on its consolidated financial statements.

~~Recently Adopted Accounting Standards~~

There was no other recently issued and effective authoritative guidance that is expected to have a material impact on the Company’s ~~condensed~~ consolidated financial statements through the reporting date.

Recently Adopted Accounting Standards

Measurement of Credit Losses on Financial Statements

In June 2016, the FASB issued ASU No. 2016-13, “Financial Instruments-Credit Losses (Topic 326):”- Measurement of Credit Losses on Financial Instruments”, or ASU 2016-13, supplemented by ASU 2018-19, “Codification Improvements to Topic 326, Financial Instruments – Credit Losses”, or ASU 2018-19. The new standard requires entities to measure all expected credit losses for financial assets held at the reporting date based on historical experience, current conditions, and reasonable and supportable forecasts. ASU 2016-13 became effective for Public Business Entities who are SEC filers for fiscal years beginning after December 15, 2019, other than smaller reporting companies, and for fiscal years beginning after December 15, 2022 for all other public business entities and private companies, with early adoption permitted. Effective January 1, 2023, the Company adopted ASU No. 2016-13. The impact of adoption of ASU 2016-13 was not material to its consolidated financial statements.

NOTE 5 - EARNINGS (LOSS) PER SHARE

Basic earnings (loss) per share is computed by dividing net income or loss available to common stockholders by the weighted-average number of common shares outstanding. Diluted earnings (loss) per share is computed by dividing net income or loss available to common stockholders by the weighted-average number of common shares plus the effect of dilutive potential common shares outstanding during the period.

The following table presents warrants included in weighted average shares outstanding due to their insignificant exercise price, during the period ~~from the date of issuance~~they were outstanding up to ~~the exercise date.~~when they were exercised. After these warrants ~~were~~are exercised the related issued and outstanding common shares are included in weighted average shares outstanding:

Issuance Date

Exercise Date

~~118,228~~

~~May 9, 2018~~

~~May 10, 2021~~

~~309,698~~

~~February 11, 2020~~

~~May 10, 2021~~

~~84,911~~

~~June 29, 2020~~

~~May 10, 2021~~

~~39,208~~

~~November 18, 2020~~

~~May 10, 2021~~

19,310

November 18, 2020

Outstanding

During the three ~~and nine~~ months ended ~~September 30,~~March 31, 2023 and 2022, ~~and 2021,~~ there was no dilutive effect from stock options, restricted stock units, or RSUs, or other warrants due to the Company’s net loss position. As of ~~September 30,~~March 31, 2023 and 2022, ~~and 2021,~~ there were ~~4.5~~80.2 million and ~~2.9~~4.4 million shares of common stock, respectively, ~~of option awards~~underlying outstanding options, RSUs and other warrants that were not included in the diluted shares calculation because their inclusion would have been antidilutive. ~~As of September 30, 2022 and December 31, 2021, there were 24.3 million and 0.7 million, respectively, of unexercised warrants that were not included in the diluted shares calculation.~~

NOTE 6 - FAIR VALUE MEASUREMENTS

Fair value measurements are categorized in one of the following three levels based on the lowest level input that is significant to the fair value measurement in its entirety:

Level 1 - Inputs to the valuation methodology are unadjusted quoted prices in active markets for identical assets or liabilities.

Level 2 - Observable inputs other than quoted prices in active markets for identical assets or liabilities include:

a.quoted prices for similar assets or liabilities in active markets;

b.quoted prices for identical or similar assets or liabilities in inactive markets;

c.inputs other than quoted prices that are observable for the asset or liability;

d.inputs that are derived principally from or corroborated by observable market data by correlation or other means.

If the asset or liability has a specified (contractual) term, the Level 2 input must be observable for substantially the full term of the asset or liability.

Level 3- Inputs to the valuation methodology are unobservable (i.e., supported by little or no market activity) and significant to the fair value measure.

Assets and liabilities measured at fair value on a recurring basis were as follows:
Fair Value Hierarchy
(in thousands) September 30, 2022 Level 1 Level 2 Level 3
Assets:
Cash and cash equivalents $ 27,196 $ 27,196 $ — $ —
Restricted cash 676 676 — —
Total assets $ 27,872 $ 27,872 $ — $ —

Fair Value Hierarchy
(in thousands) December 31, 2021 Level 1 Level 2 Level 3
Assets:
Cash and cash equivalents $ 19,689 $ 19,689 $ — $ —
Restricted cash 400 400 — —
Total assets $ 20,089 $ 20,089 $ — $ —


			Fair Value Hierarchy
(in thousands)	March 31, 2023		Level 1		Level 2		Level 3
Liabilities:
Warrants liabilities	$	23,378	$	—	$	—	$	23,378
Total liabilities	$	23,378	$	—	$	—	$	23,378

As of December 31, 2022, there were no assets and liabilities accounted for at fair value on a reoccurring basis.

The carrying amount of the Company's term loan approximates fair value based upon market interest rates available to usthe Company for debt of similar risk and maturities. ~~Refer to~~See Note 8, ~~Debt,~~ for further ~~information.~~information regarding the Company’s term loan. The carrying amount of cash and cash equivalents and restricted cash approximates fair value. See Note 12, for further details regarding the Company's Warrants and fair value measurement of Warrant liabilities.

NOTE 7 - BALANCE SHEET AND OTHER INFORMATION

Restricted cash

The Company considers cash to be restricted when withdrawal or general use is legally restricted. ~~During the nine months ended September 30, 2022, the Company recovered the $0.1 million restricted cash balance outstanding at December 31,~~In 2021 ~~that was held as a guarantee for certain purchasing cards. During the same period,~~ pursuant to a Loan and Security Agreement with Silicon Valley Bank ~~dated June 7, 2021~~ (see Note 8), the Company issued letters of credit to secure certain operating leases, and the Company is required to maintain a $0.7 million balance with the bank to secure the outstanding letters of ~~credit, of which $0.3 million was issued in February 2022.~~credit. Due to the nature of the deposit, the balance is classified as restricted cash. Restricted cash is included in ~~the balance for~~ cash and cash equivalents ~~and restricted cash~~ presented in the statements of cash flows.

Accounts Receivable

Accounts receivable are primarily comprised of trade receivables presented net of allowance for doubtful accounts when estimatable and present. The Company maintains an allowance for doubtful accounts based on its assessment of the collectability of amounts owed by customers. The allowance consists of known specific troubled accounts as well as an amount based on overall estimated potential uncollectible accounts receivable based on historical experience. As of March 31, 2023, and December 31, 2022, based upon its historical collections experience, the Company had no credit risks balances which would require to be reserved as an allowance for doubtful accounts.

Inventory

The following table presents detail of inventory balances:


		September 30,		December 31,			March 31,		December 31,
(in thousands)	(in thousands)	2022		2021		(in thousands)	2023		2022
Inventory:	Inventory:					Inventory:
MedCenter hardware	MedCenter hardware	$	2,464	$	1,201	MedCenter hardware	$	8,011	$	3,331
Pharmaceuticals		3,275		2,150
Spare parts	Spare parts	662		565		Spare parts	690		663
Total inventory	Total inventory	$	6,401	$	3,916	Total inventory	$	8,701	$	3,994

~~Pharmaceutical inventory was~~MedCenter hardware recognized in pharmacy and hardware cost of products sold at $9.3 million and $5.0 million during the three months ended September 30, 2022 and 2021, respectively, and $26.4 million and $12.2 million during the nine months ended September 30, 2022 and 2021, respectively. MedCenter hardware was ~~recognized in pharmacy and hardware cost of products sold at $0.01~~$0.2 million and $0.1 million during the three months ended ~~September 30,~~March 31, 2023 and 2022, respectively. See Property, plant, and ~~2021, respectively, and $0.2 million and $0.5 million during the nine months ended September 30, 2022 and 2021, respectively.~~equipment below for additional details.

1314

Prepaid expenses and other current assets

The following table presents prepaid expenses and other current assets balances:

September 30, December 31,
(in thousands) 2022 2021
Prepaid expenses and other current assets:
Prepaid MedCenter inventory $ 2,204 $ 1,050
Prepaid insurance 292 509
Other 367 632
Total prepaid expenses and other current assets $ 2,863 $ 2,191


	March 31,		December 31,
(in thousands)	2023		2022
Prepaid expenses and other current assets:
Prepaid MedCenter inventory	$	1,146	$	1,359
Prepaid insurance	690		921
Other	236		289
Total prepaid expenses and other current assets	$	2,072	$	2,569

Property, plant and equipment ~~net~~

The following ~~table presents~~tables present property, plant and equipment balances:


		Estimated useful lives	September 30,		December 31,			Estimated useful lives	March 31,		December 31,
(in thousands)	(in thousands)		2022		2021		(in thousands)		2023		2022
Property, plant and equipment:	Property, plant and equipment:						Property, plant and equipment:
MedCenter equipment	MedCenter equipment	8 years	$	7,525	$	5,875	MedCenter equipment	8 years	$	1,531	$	7,983
IT equipment	IT equipment	1 - 3 years	2,390		2,361		IT equipment	1 - 3 years	2,002		1,908
Leasehold improvements	Leasehold improvements	lesser of useful life or term of lease	980		880		Leasehold improvements	lesser of useful life or term of lease	316		316
General plant and equipment	General plant and equipment	5 - 8 years	619		603		General plant and equipment	5 - 8 years	373		373
Office furniture and equipment	Office furniture and equipment	5 - 8 years	538		394		Office furniture and equipment	5 - 8 years	332		217
Vehicles	Vehicles	5 years	54		54		Vehicles	5 years	38		36
Construction-in-process	Construction-in-process		481		1,021		Construction-in-process		5		5
Total historical cost	Total historical cost		12,587		11,188		Total historical cost		4,597		10,838
Accumulated depreciation	Accumulated depreciation		(6,217)		(5,496)		Accumulated depreciation		(3,808)		(5,577)
Total property, plant and equipment, net	Total property, plant and equipment, net		$	6,370	$	5,692	Total property, plant and equipment, net		$	789	$	5,261

Depreciation expense of property and equipment was ~~$0.3~~$0.7 million and $0.3 million for the three months ended ~~September 30,~~March 31, 2023 and 2022, ~~and 2021, respectively, and $0.9 million and $0.9 million for the nine months ended September 30, 2022 and 2021,~~ respectively. Depreciation expense included in pharmacy and hardware cost of products sold was ~~$0.03 million~~$9.0 thousand and ~~$0.05 million~~$26.0 thousand for the three months ended ~~September 30,~~March 31, 2023 and 2022, ~~and 2021, respectively, and $0.1 million and $0.1 million for~~respectively. During the ~~nine~~three months ended ~~September 30, 2022,~~March 31, 2023, as part of its strategic realignment, the Company decommissioned MedCenters operating under its discontinued retail pharmacy services business, and ~~2021, respectively.~~

reclassified out of property, plant, and equipment, and into inventory, for sale to customers, MedCenters with a net book value of $4.8 million, consisting of $6.7 million of gross book value partially offset by $1.9 million of accumulated depreciation.

Intangible assets ~~net~~

The following table presents intangible asset balances:


		September 30,		December 31,			March 31,		December 31,
(in thousands)	(in thousands)	2022		2021		(in thousands)	2023		2022
Gross intangible assets:	Gross intangible assets:					Gross intangible assets:
Intellectual property	Intellectual property	$	3,857	$	3,857	Intellectual property	$	3,857	$	3,857
Software	Software	5,321		4,475		Software	2,200		2,200
Website and mobile application	Website and mobile application	583		583		Website and mobile application	534		534
Total intangible assets	Total intangible assets	9,761		8,915		Total intangible assets	6,591		6,591
Accumulated amortization:	Accumulated amortization:					Accumulated amortization:
Intellectual property	Intellectual property	(3,857)		(3,857)		Intellectual property	(3,857)		(3,857)
Software	Software	(3,741)		(2,175)		Software	(1,775)		(1,749)
Website and mobile application	Website and mobile application	(583)		(583)		Website and mobile application	(534)		(534)
Total accumulated amortization	Total accumulated amortization	(8,181)		(6,615)		Total accumulated amortization	(6,166)		(6,140)
Total intangible assets, net	Total intangible assets, net	$	1,580	$	2,300	Total intangible assets, net	$	425	$	451

No intangible assets were purchased for the three months ended September 30, 2022. The Company purchased $0.7 million of intangible assets for the three months ended September 30, 2021, and $0.9 million and $1.9 million for the nine months ended September 30, 2022 and 2021, respectively.

Amortization expense of intangible assets was ~~$1.3 million~~$26.0 thousand and ~~$0.1 million~~$2.0 thousand for the three months ended ~~September 30,~~March 31, 2023 and 2022, ~~and 2021, respectively, and $1.6 million and $0.2 million for the nine months ended September 30, 2022 and 2021,~~ respectively, and are included in operating expenses.

~~The Company’s management team is evaluating its existing systems and software.~~If management were to determine that certain systems or software were to be replaced in order to achieve greater efficiencies, cost savings, or both, the estimated remaining useful life of some IT equipment and intangible assets may be reduced, resulting in higher depreciation and amortization expense, respectively.

Lessee leases

Balance sheet amounts for lease assets and leases liabilities are as follows:

September 30, December 31,
(in thousands) 2022 2021
Assets:
Operating $ 2,110 $ 2,376
Finance 160 162
Total assets $ 2,270 $ 2,538
Liabilities:
Operating:
Current $ 632 $ 599
Long-term 1,673 1,947
Finance:
Current 96 83
Long-term 65 80
Total liabilities $ 2,466 $ 2,709


	March 31,		December 31,
(in thousands)	2023		2022
Assets:
Operating	$	559	$	620
Finance	214		4
Total assets	$	773	$	624
Liabilities:
Operating:
Current	$	207	$	241
Long-term	413		441
Finance:
Current	37		5
Long-term	177		—
Total liabilities	$	834	$	687

The following table summarizes the weighted-average remaining lease term and weighted-average discount rate related to the Company’s leases as follows:


		September 30,		December 31,			March 31,		December 31,
(in thousands)		2022		2021
							2023		2022
Finance leases:						Finance leases:
Weighted-average remaining lease term (years)						Weighted-average remaining lease term (years)	4.7		0.5
Weighted-average discount rate						Weighted-average discount rate	11.4	%	6.0	%
Operating leases:	Operating leases:					Operating leases:
Weighted-average remaining lease term (years)	Weighted-average remaining lease term (years)	3.8		4.2		Weighted-average remaining lease term (years)	3.5		3.6
Weighted-average discount rate	Weighted-average discount rate	6.9	%	6.9	%	Weighted-average discount rate	6.2	%	7.3	%
Finance leases:
Weighted-average remaining lease term (years)		1.8		1.5
Weighted-average discount rate		8.6	%	8.8	%

Maturities of operating leases liabilities ~~as of September 30, 2022,~~ are as ~~follows, in thousands:~~follows:


Remaining period in 2022		$	202
2023		755
(in thousands)				(in thousands)
Remaining period in 2023				Remaining period in 2023	$	211
2024	2024	617		2024	148
2025	2025	534		2025	152
2026	2026	468		2026	157
2027	2027	64		2027	37
Thereafter		—

Total lease payments	Total lease payments	2,640		Total lease payments	705
Less: present value discount	Less: present value discount	(335)		Less: present value discount	(85)
Total leases	Total leases	$	2,305	Total leases	$	620

Maturities of finance lease liabilities ~~as of September 30, 2022,~~ are as ~~follows, in thousands:~~follows:


(in thousands)				(in thousands)
Remaining period in 2023				Remaining period in 2023	$	47
2024				2024	58
2025				2025	58
2026				2026	58
2027				2027	58

Remaining period in 2022		$	30
2023		91
2024		49
2025		4

Thereafter		—
Total finance lease payments	Total finance lease payments	174		Total finance lease payments	279
Less: imputed interest	Less: imputed interest	(13)		Less: imputed interest	(65)
Total leases	Total leases	$	161	Total leases	$	214

Operating lease ~~expenses were $0.2~~expense was $0.1 million ~~and $0.3 million~~ for each of the three months ended ~~September 30,~~March 31, 2023 and 2022, ~~and 2021, respectively, and $0.7 million and $0.7 million for the nine months ended September 30, 2022 and 2021,~~ respectively.

NOTE 8 - DEBT

The following table presents debt balances:


		September 30,		December 31,			March 31,		December 31,
(in thousands)	(in thousands)	2022		2021		(in thousands)	2023		2022
Term loan	Term loan	10,162		10,070		Term loan	$	2,002	$	5,182
Term loan issuance costs, net	Term loan issuance costs, net	(411)		(532)		Term loan issuance costs, net	(574)		(384)

Total long-term debt, net		$	9,751	$	9,538
Total debt, net						Total debt, net	1,428		4,798
Less short term debt						Less short term debt	—		—
Long-term debt, net						Long-term debt, net	$	1,428	$	4,798

Term loan

The ~~term~~Term loan bears interest at a floating rate equal to the greater of 7.25% or the Prime Rate plus 4.0% ~~(10.25%~~(12.0% at ~~September 30, 2022)~~March 31, 2023).

First Amendment, Consent and Default Waiver to Loan and Security Agreement

On February 10, 2023, the Company entered into the First Amendment, Consent and Default Waiver to Loan and Security Agreement or the Loan Amendment and Consent, with each of Silicon Valley Bank, a California corporation, and an authorized foreign bank under the Bank Act (Canada), and SVB Innovation Credit Fund VIII, L.P., a Delaware limited partnership, or together SVB. Among other matters, the Loan Amendment and Consent provides SVB’s consent to the sale of certain assets related to the Company’s pharmacy services business pursuant to the previously announced Asset Purchase Agreement. The ~~term loan matures on April 1, 2026. Principal repayment will commence on May 1, 2024 in equal monthly installments~~Loan Amendment and Consent also provides that upon the closing of the ~~outstanding loan balance through~~asset sale, the ~~maturity date.~~Company would pay SVB $3.4 million, which includes $0.4 million of the Final Payment (as defined in the Loan Amendment and Consent) and prepayment of $3.0 million of Term Loan Advances (as defined in the Loan Amendment and Consent), with SVB waiving the prepayment premium due on all Term Loan Advances prepaid by the Company prior to February 10, 2023. The Loan Amendment and Consent also includes SVB's waiver of any legal action or enforcement of rights and remedies with respect to certain specified defaults arising prior to February 10, 2023.

On February 10, 2023, in connection with the Loan Amendment and Consent, the Company issued warrants, or the SVB Warrants, to SVB for the purchase of up to an aggregate of 200,366 shares of common stock at a per share exercise price of $0.3274, with an expiration date of February 10, 2035. The number of shares and the exercise price are subject to adjustment as set forth in the SVB Warrants. See Note 12.

SVB Letter Agreement

On March 13, 2023, the Company was informed by SVB that the Company was still bound by the terms, conditions, and covenants of the Company’s Loan and Security Agreement with SVB, or the Loan Agreement, and the Loan Amendment and Consent. On March 29, 2023, the

Company entered into a Letter Agreement, or Letter Agreement, with each of (a) Silicon Valley Bank, a Division of First-Citizens Bank & Trust Company (successor by purchase to the Federal Deposit Insurance Corporation as receiver for Silicon Valley Bridge Bank, N.A. (as successor to Silicon Valley Bank)), or SVB Successor, in its capacity as administrative agent and collateral agent, (b) SVB Successor, as a lender, and (c) SVB Innovation Credit Fund VIII, L.P., or SVB Capital, as a lender, and obtained a waiver for any event of default occurring prior to March 29, 2023, to include the year ended December 31, 2022. The Letter Agreement also amends the Loan Agreement to provide that the Company is only required to maintain on deposit at SVB Successor or its affiliates, at least 50% of the aggregate dollar value of all of the Company accounts at all financial institutions.

As of March 31, 2023, the Company had approximately $9.8 million on deposit with SVB Successor and $9.7 million on deposit with another financial institution and was in compliance with all required covenants of the Loan Agreement. The Company continues to monitor the circumstances surrounding SVB and does not anticipate such circumstances will have a material impact on the Company's financial condition, operations, or on the Loan Agreement with SVB Successor. As of the date of filing this Quarterly Report on Form 10-Q, the Company has full access to and control over all of its cash, and cash equivalents across all financial institutions.

NOTE 9 - INCOME TAXES

The Company incurred ~~$0.02 million and zero of~~minimal income tax expense for the ~~nine~~three months ended ~~September 30,~~March 31, 2023 and 2022, due to ongoing losses and ~~2021, respectively. The~~minimum state income ~~taxes for the periods ended September 30, 2022, are primarily attributed to certain state taxes. The Company continues to be in a loss position as of September 30, 2022.~~tax obligations. The effective income tax rate in each period differed from the federal statutory tax rate of 21% primarily as a result of the ongoing losses.

As of ~~September 30,~~March 31, 2023 and December 31, 2022, the Company recorded a full valuation allowance against all of its net deferred tax assets due to the uncertainty surrounding the Company’s ability to utilize these assets in the ~~foreseeable~~ future.

On August 16, 2022, the U.S. enacted the Inflation Reduction Act of 2022, which, among other things, implements a 15% minimum tax on book income of certain large corporations, a 1% excise tax on net stock repurchases and several tax incentives to promote clean energy. The Company has evaluated the impacts of this legislation to the financial statements but does not expect them to be material.

NOTE 10 - COMMITMENTS AND CONTINGENCIES

~~Legal~~Litigation

~~Following MYOS Rens Technology Inc.’s, or MYOS’s~~The Company is and, ~~MedAvail, Inc.’s, or MAI's, announcement~~from time to time may in the future become, involved in legal proceedings, claims and litigation in the ordinary course of business. The Company has become subject to certain demands, and claims from former employees relating to the reduction in force the Company implemented in connection with the restructuring of the ~~execution~~company and the disposition of its pharmacy services business. The Company intends to vigorously defend itself against such pending and threatened actions. The Company cannot determine a reasonable estimate of the Merger Agreement on June 30, 2020, MYOS received separate litigation demands from purported MYOS stockholders on September 16, 2020 and October 20, 2020, respectively seeking certain additional disclosures in the Form S-4 Registration Statement filed with the Securities and Exchange Commission on September 2, 2020, collectively, the Demands. Thereafter, on September 23, 2020, a complaint regarding the transactions contemplated within the Merger Agreement was filed in the Supreme Courtmaximum possible loss or range of loss for pending or threatened matters given that they are at various stages of the ~~State~~litigation process and each case is subject to the inherent uncertainties of ~~New York, County~~litigation. In management’s opinion, based on currently available information, any potential loss resulting from the resolution of ~~New York, captioned Faasse v. MYOS RENS Technology Inc., et. al., Index No.: 654644/2020 (NY Supreme Ct., NY Cnty., September 23, 2020),~~these matters is not expected to have a material adverse effect on the Company’s results of operations, financial position, or the New York Complaint. On October 12, 2020, a second complaint regarding the transactions was filed in the District Court of Nevada, Clark County Nevada, captioned Vigil v. Mannello, et. al., Case No. A-20-822848-C, or the Nevada Complaint, and together with the New York Complaint, the Complaints, and collectively with the Demands, the Litigation.

The Demands and the Complaints that comprised the Litigation generally alleged that the directors of MYOS breached their fiduciary duties by entering into the Merger Agreement, and MYOS and MAI disseminated an incomplete and misleading Form S-4 Registration Statement. The New York Complaint also alleged MedAvail aided and abetted such breach of fiduciary duties.

MYOS and MAI believe that the claims asserted in the Litigation were without merit, and believe that the Form S-4 Registration Statement disclosed all material information concerning the Merger and no supplemental disclosure was required under applicable law. However, in order to avoid the risk of the Litigation delaying or adversely affecting the Merger and to minimize the costs, risks and uncertainties inherent in litigation, and without admitting any liability or wrongdoing, MYOS determined to voluntarily supplement the Form S-4 Registration Statement as described in the Current Report on Form 8-K on November 2, 2020. Subsequently, the Nevada Complaint and the New York Complaint were voluntarily dismissed. MYOS and MAI specifically deny all allegations in the Litigation and/or that any additional disclosure was or is required, and none of the Litigation remains currently pending.cash flows.

NOTE 11 - ~~EQUITY,~~ SHARE-BASED COMPENSATION ~~AND WARRANTS~~

On June 14, 2022, the Company’s stockholders approved an Amended and Restated Certificate of Incorporation to increase the number of authorized shares of the Company’s common stock, par value $0.001, from 100 million shares to a new total of 300 million shares. The Restated Certificate was effective upon filing the Restated Certificate with the Secretary of State of the State of Delaware on June 15, 2022.

~~Private Placement~~

On March 30, 2022, the Company entered into a Securities Purchase Agreement, or Purchase Agreement, with certain purchasers thereto, or the Investors. Pursuant to the Purchase Agreement, the Company agreed to issue and sell to the Investors in a private placement, or the Private Placement, up to 47.1 million shares, or the Shares, of the Company’s common stock, and to issue warrants, or the Warrants, to purchase up to 23.5 million shares of common stock, or Warrant Shares. The Shares and the Warrants were sold at two closings as further described below, at a price per share of $1.0625.

Each Investor purchasing Shares in the Private Placement was issued a Warrant to purchase that number of Warrant Shares equal to 50% of the number of Shares purchased under the Purchase Agreement by such Investor. The Warrants have a per share exercise price of $1.25 and will be exercisable by the holder at any time on or after the issuance date of the Warrant for a period of five years. If the Warrants were exercised in full immediately after issuance by the Investors, the Company would receive additional gross proceeds of up to $29.4 million. In addition, the Warrant terms provide the Company with a call option to force the Warrant holders to exercise up to two-thirds of the warrant shares subject to each Warrant, with one-third of the Warrant Shares being callable beginning on each of the 12 month and 24 month anniversaries of the Warrant issuance dates, in each case until the expiration of the Warrants, and subject to the satisfaction of certain pricing conditions relating to the trading of the Company’s shares. If the Company were to exercise the contingent call options immediately after issuance, approximately $19.6 million in gross proceeds could be raised.

On April 4, 2022, the first closing of the Private Placement occurred, in which 37.6 million shares of common stock for $40.0 million in gross proceeds, before deducting placement agent commissions and other offering expenses, and Warrants exercisable for up to 18.8 million Warrant Shares were issued by the Company. A second and final closing occurred on July 1, 2022, and the Investors purchased an additional 9.4 million shares of common stock for $10.0 million in additional gross proceeds and Warrants exercisable for up to 4.7 million Warrants Shares.

~~Shelf Registration and Sales Agreement~~

On August 12, 2022, the Company filed a shelf registration statement on Form S-3, or the Shelf, with the SEC in relation to the registration and potential future issuance of common stock, preferred stock, debt securities, depositary shares, warrants, subscription rights, purchase contracts, units and/or any combination thereof, in the aggregate amount of up to $150,000,000. The Shelf was declared effective on August 26, 2022. The Company also entered into a sales agreement as of August 12, 2022, or Sales Agreement, with Cowen and Company, LLC, or Cowen, as sales agent, providing for the offering, issuance and sale of up to an aggregate $50,000,000 of the Company’s common stock from time to time at market prices by any method that is deemed to be an “at the market offering” as defined in Rule 415(a)(4) under the Securities Act, including sales made directly on the Nasdaq Capital Market or any other trading market for the Company’s common stock in “at-the-market” offerings, under the Shelf. As of September 30, 2022, the Company has not issued and sold any shares of common stock under the Sales Agreement.

Share-based compensation

The following table presents the Company's expense related to share-based compensation, ~~(in thousands):~~in thousands:

Three Months Ended September 30, Nine Months Ended September 30,
2022 2021 2022 2021
Share-based compensation $ 565 $ 365 $ 1,741 $ 948


	Three Months Ended March 31,
	2023		2022
Share-based compensation	$	618	$	564

~~The share-based compensation expense for the three and nine months ended September 30, 2022 and included $0.02 million and $0.1 million, respectively, from employee stock purchase plan expense.~~

~~The expense~~Expense remaining to be recognized for unvested option awards from the 2012, 2018, 2020 and ~~2020~~2022 plans ~~and the 2022 inducement plan~~ as of ~~September 30, 2022~~March 31, 2023, was ~~$2.4 million, which is expected to be recognized on a weighted average basis over the next 2.7 years. The expense remaining to be recognized for unvested restricted stock units was $2.2~~$1.8 million, which will be recognized on a weighted average basis over the next ~~2.3~~2.6 years. Expense remaining to be recognized for unvested RSU awards as of March 31, 2023, was $1.6 million, which will be recognized on a weighted average basis over the next 1.9 years.

The following table presents the Company's outstanding option awards activity during the ~~nine~~ three months ended ~~September 30, 2022~~:March 31, 2023:

(in thousands, except for share and per share amounts) Number of Awards Weighted Average Exercise Price Weighted Average Share Price on Date of Exercise Weighted Average Fair Value Weighted Average Remaining Contractual Life (Years) Aggregate Intrinsic Value
Outstanding, beginning of period 2,848,903 $ 2.78 $ 1.44 $ 104
Granted 2,758,040 1.35 0.98 —
Exercised/released — — — —
Expired (117,730) 1.99 1.08 5
Forfeited (952,488) 2.52 1.42 111
Outstanding, end of period 4,536,725 $ 1.93 $ 1.15 8.33 $ —
Vested and exercisable, end of the period 1,777,907 2.28 1.16 6.79 —
Vested and unvested exercisable, end of the period 1,777,907 2.28 1.16 6.79 —
Vested and expected to vest, end of the period 4,309,018 1.94 1.15 8.29 —


(in thousands, except for share and per share amounts)	Number of Awards	Weighted Average Exercise Price		Weighted Average Fair Value		Weighted Average Remaining Contractual Life (Years)	Aggregate Intrinsic Value
Outstanding, beginning of period	4,399,741	$	1.88	$	1.14		$	—
Granted	—	—		—			—
Exercised/Released	—	—		—			—
Expired	—	—		—			—
Forfeited	(66,302)	1.37		0.83			—
Outstanding, end of period	4,333,439	$	1.89	$	1.15	8.05	$	—
Vested and exercisable, end of the period	2,079,894	2.23		1.22		7.03	—
Vested and unvested exercisable, end of the period	2,079,894	2.23		1.22		7.03	—
Vested and expected to vest, end of the period	4,180,949	1.91		1.15		8.02	—

The following table ~~presents the Company's~~present outstanding ~~restricted stock unit~~RSU awards activity during the ~~nine~~three months ended ~~September 30, 2022:~~March 31, 2023:

(in thousands, except for share and per share amounts) Number of Awards Weighted Average Exercise Price Weighted Average Share Price on Date of Exercise Weighted Average Fair Value Weighted Average Remaining Contractual Life (Years) Aggregate Intrinsic Value
Outstanding, beginning of period 802,740 $ — $ 2.78 $ 1,124
Granted 1,601,824 — 1.41 2,252
Exercised/released (46,009) — $ 1.17 6.32 54
Expired — — — —
Forfeited (585,973) — 2.05 791
Outstanding, end of period 1,772,582 $ — $ 1.69 4.93 $ 1,376
Vested and exercisable, end of the period — — — —
Vested and unvested exercisable, end of the period — — — —
Vested and expected to vest, end of the period 1,628,975 — 1.69 4.92 1,264


	Number of Awards	Weighted Average Exercise Price		Weighted Average Grant Date Fair Value		Weighted Average Remaining Contractual Life (Years)
Unvested outstanding, beginning of period	2,376,554	$	—	$	1.31
Granted	—	$	—	$	—
Exercised/Released	—	$	—	$	—
Cancelled/Forfeited	(763,380)	$	—	$	0.87
Expired	—	$	—	$	—
Unvested outstanding, end of period	1,613,174	$	—	$	1.40	14.14
Vested, outstanding shares	—	$	—	$	—

AnAs of March 31, 2023 and December 31, 2022, there was an aggregate of ~~2.8~~2.7 million and ~~3.4~~2.3 million shares of common stock, ~~was~~respectively, available for grant under the 2020 ~~Plan as~~Plan. As of ~~September 30, 2022~~March 31, 2023 and December 31, ~~2021, respectively.~~2022, there was an aggregate of 1.1 million and 0.2 million shares of common stock, respectively, available for grant under the 2022 Inducement plan.

~~In April 2022, the Company adopted the MedAvail Holdings, Inc. 2022 Inducement~~

NOTE 12 - WARRANTS

Equity Incentive Plan or the Inducement Plan. The Inducement Plan reserved 1,500,000 shares of the Company’s common stock for issuance pursuant to equity awards granted under the Inducement Plan. On April 8, 2022, the Company issued inducement awards to employees that included options to purchase 426,500 shares of Company common stock, and 426,500 restricted stock units. The inducement stock options have an exercise price of $1.96, and 25% of the shares vest on the one year anniversary of the date that employment commenced, and an additional one forty-eighth (1/48th) of the shares vest monthly thereafter. The inducement restricted stock units vest at one-third (1/3rd) of the shares on the first, second and third yearly anniversaries of March 1, 2022.

Warrants

During the ~~nine~~twelve months ended ~~September 30,~~December 31, 2022, 18.8 million warrants were issued ~~from~~at the first closing of ~~the Private Placement~~a private placement in April 2022 with a fair value of ~~$7.5 million.~~$9.2 million, a 5 years term and an exercise price per share of $1.25. An additional 4.7 million warrants were issued ~~from the~~at a second closing of the ~~Private Placement~~private placement in July 2022 with a fair value of ~~$2.3 million.~~ $4.5 million, a 5 years term and an exercise price per share of $1.25.

No warrants were exercised or expired during the ~~nine~~three months ended ~~September 30,~~March 31, 2023, or twelve months ended December 31, 2022. These warrants met the equity classification requirements and therefore are classified in our stockholders' equity.

SVB warrants

During the three months ended March 31, 2023, as part of the First Amendment to the Loan and Security Agreement with Silicon Valley Bank (see Note 8), the Company issued 200,366 common stock warrants to the lenders. Upon grant date, the fair value of the warrants was $57 thousand, measured using the Black Scholes Option Pricing model. There ~~were 24.2 million related party~~was no material change in fair value of these warrants ~~outstanding as of September 30, 2022.~~through March 31, 2023.

The ~~terms for~~SVB Warrants met equity classification requirements under ASC 815 - Derivative and Hedging, specifically due to the warrants ~~issued from~~having a limit on the ~~Private Placement were as follows:~~number of shares the entity will be required to deliver upon exercise and the warrants not including cash-settled top-off or make-

September 30, 2022
Issue Date Reason for issuance Term (years) Exercise Price (USD)
April 4, 2022 Private Placement 5 $ 1.25
July 1, 2022 Private Placement 5 $ 1.25
whole provisions, as well as, other conditions. As such, the SVB warrants met the equity classification requirements and are classified in the Company's shareholder' equity.

~~NOTE 12 - REVENUE AND SEGMENT REPORTING~~

~~Operating segments are~~The key input assumptions utilized in the individual operations that the chief operating decision maker, or CODM, who is the Company's chief executive officer, reviews for purposes of assessing performance and making resource allocation decisions. The CODM currently receives the monthly management report which includes information to assess performance. The retail pharmacy services and pharmacy technology operating segments both engage in different business activities from which they earn revenues and incur expenses.

~~The Company has the following two reportable segments:~~

~~Retail Pharmacy Services Segment~~

Retail Pharmacy Services segment revenue consists of products sold directly to consumers at the point of sale. MedAvail recognizes retail pharmacy revenue, net of taxes and expected returns, at the time it sells merchandise or dispenses prescription drugs to the customer. The Company estimates revenue based on expected reimbursements from third-party payers (e.g., pharmacy benefit managers, insurance companies and governmental agencies) for dispensing prescription drugs. The estimates are based on all available information including historical experience and are updated to actual reimbursement amounts.

~~Pharmacy Technology Segment~~

The Pharmacy Technology Segment consists of sales and subscriptions of MedPlatform systems to customers. These agreements include providing the MedCenter prescription dispensing kiosk, software, and maintenance services. This generally includes either an initial lump sum payment upon installationvaluation of the MedCenter with monthly payments for software and services following, or monthly payments for the MedCenter along with monthly payments for software and maintenance services for subscription agreements.SVB Warrants were as follows:


	Grant date	March 31, 2023
Market price	$0.32	$0.29
Exercise price	$0.32	$0.32
Term (Years)	12	11.7
Volatility	85%	85%
Risk Free Rate	3.68%	3.60%

Liability warrants

The following ~~tables present revenue~~table presents liability warrants:


	March 31,	December 31,
(in thousands)	2023	2022
Pre-Funded Warrants	14,295	—
Series A Warrants	9,083	—
	23,378	—

Private placement

On March 9, 2023, the Company entered into a Securities Purchase Agreement for a private placement of securities with certain institutional investors, or the Investors. Pursuant to the terms of the Offering, the Company agreed to issue Pre-Funded Warrants upon closing at a price of $0.3212 per underlying share, and Pre-Funded Warrants are exercisable into shares of common stock at an exercise price of $0.001 per share. The number of Pre-Funded Warrants exercisable is limited by the Nasdaq 19.99% cap based on the shares of Common Stock outstanding; until the Company's stockholders approve issuing Common Stock in excess of the Nasdaq 19.99% cap at the Company's annual shareholder meeting to be held June 14, 2023. Additionally, the Company provided the Investors with Series A Warrants with an exercise price of $0.385440 per share, that are not exercisable until the stockholders approve the Company to issue Common Stock in excess of the Nasdaq 19.99% cap.

The Pre-Funded Warrant shares are exercisable for an aggregate of up to 49,813,198 shares of common stock, and the Series A Warrants will be exercisable for an aggregate of up to 49,813,198 shares of common stock. Upon close of the transaction on March 13, 2023, the Company received gross proceeds from the Offering of approximately $16.0 million, before deducting Offering expenses. The Company intends to use the net proceeds from the Offering to fund costs associated with restructuring, repay outstanding debt, and finance its growth initiatives related to its MedCenter technology business.

Upon grant, the fair value of ~~products sold~~the Pre-Funded Warrants and ~~services by segment (in thousands):~~Series A Warrants was $15.9 million and $10.5 million, respectively. The Company recorded the $10.4 million difference between the Offering proceeds and grant date fair value as a loss on issuance of warrants in the statement of operations and comprehensive loss. The fair values of the awards were measured using the Black Scholes Option Pricing model as of the grant date.

The key input assumptions utilized in the valuation of the Pre-funded Warrants were as follows:


	Grant date	March 31, 2023
Market price	$0.32	$0.29
Exercise price	$0.001	$0.001
Term (Years)	12	11.7
Volatility	85%	85%
Risk Free Rate	3.70%	3.67%

Retail Pharmacy Services Pharmacy Technology Total
Three Months Ended September 30, 2022
Revenue:
Pharmacy and hardware revenue:
Retail pharmacy revenue $ 11,162 $ — $ 11,162
Hardware — — —
Subscription — 104 104
Total pharmacy and hardware revenue 11,162 104 11,266
Service revenue:
Software — 94 94
Maintenance and support — 48 48
Installation — — —
Professional services and other — 53 53
Total service revenue — 195 195
Total revenue 11,162 299 11,461
Cost of products sold and services 10,047 122 10,169
Segment gross profit $ 1,115 $ 177 1,292
Operating expense:
Pharmacy operations 4,392
General and administrative 6,087
Selling and marketing 2,126
Research and development 178
Total operating expense 12,783
Operating loss $ (11,491)

The key input assumptions utilized in the valuation of the Series A Warrants were as follows:


	Grant date	March 31, 2023
Market price	$0.32	$0.29
Exercise price	$0.39	$0.39
Term (Years)	5	4.9
Volatility	85%	85%
Risk Free Rate	3.68%	3.60%

The fair values of the Pre-Funded Warrants and Series A Warrants decreased $1.6 million and $1.4 million, respectively, during the three months ended March 31, 2023; which is included in the gain from change in fair value of warrants on the statement of operations and comprehensive loss.

NOTE 13 - DISCONTINUED OPERATIONS

As discussed in Note 1 – Nature of Operations – the exit of our pharmacy services business was substantially completed as of March 31, 2023. The pharmacy services business was previously a reportable segment and the exit represents a strategic shift in the Company going forward. Accordingly, with the sale or disposition of its retail pharmacy assets and exit of the pharmacy services business, this transaction meets the accounting requirements for reporting as discontinued operations under ASC 205-20-50 for all periods presented.

The following table summarizes the major income and expense line items from discontinued operations as reported in the condensed consolidated statements of operations and comprehensive loss:


	Three Months Ended March 31,
(in thousands)		2023		2022
Revenue:
Pharmacy revenue		$	3,834	$	8,849
Total revenue		3,834		8,849
Cost of products sold and services:
Pharmacy cost of products sold		3,581		8,481
Total cost of products sold and services		3,581		8,481
Operating expense:







Pharmacy operations		1,726		3,720
General and administrative		570		1,563
Selling and marketing		845		2,205
Research and development		—		235

Total operating expense		3,141		7,723
Operating loss		(2,888)		(7,355)
Loss from sale and disposition of net assets, and reorganization expenses, net		(1,885)		—

Interest expense		1		(3)


Loss from discontinued operations		$	(4,772)	$	(7,358)

Cash provided by operating activities by the pharmacy services business totaled $3.5 million and $0.1 million for the three months ended March 31, 2023 and March 31, 2022, respectively. Cash used in investing activities from the pharmacy services business totaled totaled $0.02 million and $0.35 million for the three months ended March 31, 2023 and March 31, 2022, respectively. Cash used in financing activities from the pharmacy services business totaled totaled $0.03 million and $0.02 million for the three months ended March 31, 2023 and March 31, 2022, respectively. Depreciation and amortization expense of the pharmacy services business totaled totaled $0.75 million and $0.48 million for the three months ended March 31, 2023 and March 31, 2022, respectively. The condensed consolidated statements of cash flows included $0.8 million loss on disposal of net assets from discontinued operations, which comprised of losses related to net realizable value adjustments to right of use assets related to leases and prepaid assets, and abandonment of certain property, plant, and equipment related to our discontinued operations.

Retail Pharmacy Services Pharmacy Technology Total
Three Months Ended September 30, 2021
Revenue:
Pharmacy and hardware revenue:
Retail pharmacy revenue $ 5,445 $ — $ 5,445
Hardware — 106 106
Subscription — 108 108
Total pharmacy and hardware revenue 5,445 214 5,659
Service revenue:
Software — 51 51
Maintenance and support — 44 44
Installation — 11 11
Professional services and other — 27 27
Total service revenue — 133 133
Total revenue 5,445 347 5,792
Cost of products sold and services 5,366 240 5,606
Segment gross profit $ 79 $ 107 186
Operating expense:
Pharmacy operations 3,750
General and administrative 5,320
Selling and marketing 1,909
Research and development 232
Total operating expense 11,211
Operating loss $ (11,025)

Retail Pharmacy Services Pharmacy Technology Total
Nine Months Ended September 30, 2022
Revenue:
Pharmacy and hardware revenue:
Retail pharmacy revenue $ 30,652 $ — $ 30,652
Hardware — 236 236
Subscription — 322 322
Total pharmacy and hardware revenue 30,652 558 31,210
Service revenue:
Software — 228 228
Maintenance and support — 127 127
Installation — 77 77
Professional services and other — 117 117
Total service revenue — 549 549
Total revenue 30,652 1,107 31,759
Cost of products sold and services 28,460 588 29,048
Segment gross profit $ 2,192 $ 519 2,711
Operating expense:
Pharmacy operations 11,970
General and administrative 18,729
Selling and marketing 6,738
Research and development 952
Total operating expense 38,389
Operating loss $ (35,678)

Retail Pharmacy Services Pharmacy Technology Total
Nine Months Ended September 30, 2021
Revenue:
Pharmacy and hardware revenue:
Retail pharmacy revenue $ 13,357 $ — $ 13,357
Hardware — 470 470
Subscription — 338 338
Total pharmacy and hardware revenue 13,357 808 14,165
Service revenue:
Software — 125 125
Maintenance and support — 115 115
Installation — 39 39
Professional services and other — 405 405
Total service revenue — 684 684
Total revenue 13,357 1,492 14,849
Cost of products sold and services 13,130 1,040 14,170
Segment gross profit $ 227 $ 452 679
Operating expense:
Pharmacy operations 9,428
General and administrative 16,733
Selling and marketing 5,056
Research and development 601
Total operating expense 31,818
Operating loss $ (31,139)

The following table ~~presents~~summarizes the major classes of assets and liabilities ~~by segment (in thousands):~~

Retail Pharmacy Services Pharmacy Technology Corporate Total
September 30, 2022
Assets $ 15,939 $ 7,953 $ 25,959 $ 49,851
Liabilities $ 5,841 $ 2,689 $ 10,015 $ 18,545
December 31, 2021
Assets $ 13,641 $ 5,222 $ 19,280 $ 38,143
Liabilities $ 5,618 $ 3,567 $ 9,885 $ 19,070

~~The following table presents long-lived assets, which include property, plant, and equipment and right-of-use-assets by geographic region, based~~of the retail pharmacy business as reported on the ~~physical location of the assets (in thousands):~~condensed consolidated balance sheets:

September 30, December 31,
2022 2021
Long-lived assets:
United States $ 8,286 $ 7,675
Canada 354 555
Total long-lived assets $ 8,640 $ 8,230


(in thousands)	March 31, 2023		December 31, 2022
Carrying amounts of major classed of assets included as part of discontinued operations:
Accounts receivable, net	$	2,065	$	1,804
Prepaid expenses and other current assets	14		95
Inventories	—		2,943
Total current assets from discontinued operations	$	2,079	$	4,842

Intangible assets, net	$	—	$	14
Property plant and equipment, net	—		1,194
Right-of-use assets	998		1,461
Other assets	168		168
Total long-term assets from discontinued operations	$	1,166	$	2,837

Total long-term assets from discontinued operations
Accounts payable	$	290	$	857
Accrued liabilities	1,105		642
Accrued payroll and benefits	28		834
Current portion of lease obligations	462		461
Total current liabilities from discontinued operations	$	1,885	$	2,794

Long-term portion of lease obligations	$	1,015	$	1,128
Total long-term liabilities from discontinued operations	$	1,015	$	1,128

NOTE ~~13 –~~14 - SUBSEQUENT EVENTS

Reduction in Force

~~Nasdaq Capital Market Listing Qualifications~~

~~The Company received a deficiency letter from the Listing Qualifications Department of the Nasdaq Capital Market (“Nasdaq”) on October 31, 2022 notifying~~On April 27, 2023, the Company ~~that for the last 30 consecutive business days the bid price for the Company’s common stock had closed below the minimum $1.00 per share requirement for continued inclusion~~completed an additional reduction in ~~Nasdaq Capital Market pursuant to Nasdaq Listing Rule 5550(a)(2) (the “Bid Price Rule”). The deficiency letter will not result~~force, in ~~the immediate delisting~~which approximately 27% of the Company’s ~~common stock from Nasdaq.~~

full-time employees at that time, were terminated, effective April 28, 2023. The Company ~~has an initial period~~notified the employees of ~~180 calendar days, or until May 1, 2023, to regain compliance~~their termination on April 27, 2023. The reduction in force is in connection with the ~~Bid Price Rule. If the~~Company’s continued efforts to streamline operations and achieve cost savings while focusing on its pharmacy technology business. The Company ismay incur additional expenses not ~~in compliance~~currently contemplated due to events associated with the Bid Price Rule within the first 180 calendar days, the Company may be afforded a second 180 calendar day period to regain compliance. To qualify, the Company would be required to meet the continued listing requirement for market value of publicly held shares and all other initial listing standards required by Nasdaq, except for the minimum bid price requirement.

reduction in force. The Company intends to monitor the closing bid price of its common stock and may, if appropriate, consider available options to regain compliance with the Bid Price Rule, including initiating a reverse stock split. However, there can be no assurancechanges that the Company ~~will be able~~expects to ~~regain compliance~~incur in connection with the ~~Bid Price Rule or will otherwise be~~reduction in ~~compliance with other Nasdaq Listing Rules. If we do not regain compliance with the Bid Price Rule~~force are estimates and ~~are not eligible for an additional compliance period, our common stock~~subject to a number of assumptions, and actual results may be delisted. For more information, see “Risk Factors - Our share price does not meet the minimum bid price for continued listing on Nasdaq. Our ability to continue operations or to publicly or privately sell equity securities and the liquidity of our common stock could be adversely affected if we do not regain compliance with the minimum bid price requirement and we are delisted from Nasdaq.”differ materially.

2522

Item 2. ~~MANAGEMENT’S DISCUSSION AND ANALYSIS OF FINANCIAL CONDITION AND RESULTS OF OPERATIONS~~Management's Discussion and Analysis of Financial Condition and Results of Operations

~~You should read the~~The following discussion should be read in conjunction with our audited historical condensed consolidated financial statements for the year ended December 31, ~~2021,~~2022 which are included in the Annual Report on Form 10-K, filed with the Securities and Exchange Commission on ~~March 29, 2022,~~April 14, 2023, and our unaudited condensed consolidated financial statements and accompanying footnotes for the three ~~and nine~~ months ended ~~September 30, 2022~~March 31, 2023, included ~~elsewhere in~~Part I, Item 1., of this Quarterly Report on Form 10-Q.

This ~~Management's~~quarterly Report on Form 10-Q, including "Management's Discussion and Analysis of Financial Condition and Results of Operations," contains statements that are ~~forward-looking.~~forward-looking regarding future events and our future results subject to the safe harbor created under the Private Securities Litigation Reform Act of 1995 and other safe harbors under the Securities Act of 1933, as amended, and the Securities Exchange Act of 1934, as amended. Words such as “anticipate”, “estimate”, “expect”, “project”, “plan”, “intend”, “believe”, “may”, “might”, “will”, “should”, “can have”, “likely” and similar expressions are used to identify forward-looking statements.

All forward-looking statements are subject to risks and uncertainties that may cause actual results to differ materially from those that we expect. These statements are based on current expectations and assumptions that are subject to risks, uncertainties and other factors. Actual results could differ materially because of the factors discussed ~~below or~~above and elsewhere in this Quarterly Report on Form 10-Q. See Part II, Item 1A. "Risk Factors" of this Quarterly Report on Form 10-Q, and Part I, Item 1A. "Risk Factors" of ~~the 2021~~our Annual Report on Form 10-K for the year ended December 31, ~~2021.~~2022. Unless otherwise indicated or the context otherwise requires, references herein to “MedAvail,” “MedAvail Holdings,” “we,” “us,” “our,” and the “Company” refers to MedAvail Holdings, Inc. and its subsidiaries.

Overview

We are a technology-enabled ~~retail~~ pharmacy technology ~~and~~ services company, weand have developed and commercialized an innovative self-service pharmacy, mobile application, and kiosk. Through our full-stack pharmacy technology platform, and personal one-on-one service, we bring pharmacy-dispensing capability to the point of care, resulting in lower costs, higher patient satisfaction, improved medication adherence, and better health outcomes.

We offer a unique, pharmacy technology solution which is anchored around our core technology called the MedAvail MedCenter™, or the MedCenter. The MedCenter enables on-site pharmacy in medical clinics, retail store locations, employer sites with and without onsite clinics, and any other location where onsite prescription dispensing is desired. The MedCenter establishes an audio-visual connection to a live pharmacist enabling remote prescription drug dispensing to occur directly to a patient while still providing real-time supervision by a pharmacist. ~~Although~~

Currently, our ~~technology platform has broad application, we are currently focused on serving high-value Medicare members in~~primary and only commercialization channel is the ~~United States of America, or U.S.~~

We currently deploy the MedCenter solution through two distinct commercialization channels. First, we own and operate a full retail pharmacy business in the U.S. under the name SpotRx™, or SpotRx. The SpotRx pharmacy business is structured as a hub-and-spoke model where a central pharmacy supports and operates MedCenter kiosks embedded in medical clinics, usually in close proximity to the central pharmacy. Second, as a direct ‘sell-to’ model, ~~commercialization channel,~~whereby we sell or lease the MedCenter hardware technology and ~~subscriptions for~~provide recurring, one-time, or on demand services related to the ~~associated software~~MedCenter directly to large healthcare providers and retailers for use within their own pharmacy operations. We deploy the MedCenter solution currently to locations to include, but not limited to, urgent care and emergency medical facility locations, in clinic locations of large healthcare providers, and University campuses.

The MedCenter kiosk works in tandem with our Remote Dispensing System®, or the Remote Dispensing System, which consists of customer-facing software for remote ordering of medications for pick-up at a ~~MedCenter, or next day home delivery.~~MedCenter. Supporting our MedCenter kiosks and Remote Dispensing System ~~are~~is our back-end MedPlatform® Enterprise Software, or the MedPlatform Enterprise Software, which controls dispensing and MedCenter monitoring, and supporting Pharmacy Management System ~~software, which allows~~software.

Our kiosks come in one model: the M4 MedCenter. The M4 MedCenter is designed to fit in waiting rooms, hallways, and lobbies.

Discontinued Operations

On January 19, 2023, we announced our plan to exit the retail pharmacy services business, or the “Pharmacy Services Business”, to focus on our Pharmacy Technology services. In connection with our exit from the Pharmacy Services Business, we hired a broker and negotiated the sale of certain related pharmacy assets. Our operations following the exit from the Pharmacy Services Business consist solely of our Pharmacy Technology services. On April 6, 2023, we announced that we had completed the transactions contemplated by the Asset Purchase Agreement, including the disposition of the specific assets therein, on February 10, 2023. As of March 31, 2023, we have substantially completed our exit from the Pharmacy Services Business.

Prior to Discontinued Operations, during the three months ended March 31, 2023, we had two reportable segments: retail pharmacy services and pharmacy technology services. As a result of the retail pharmacy services business exit, the Company met the requirements of ASC 205-20, to report the results of the retail pharmacy services business as a discontinued operation. Accordingly, the operating results for the retail pharmacy services business have therefore been reclassified as a discontinued operation within these condensed consolidated financial statements. As such, unless otherwise noted, the discussion of our ~~supporting team~~operating results, Results of ~~pharmacists~~Operations, and ~~kiosk administrators.~~

~~Traditional retail pharmacies are built around a physical store front. In order~~Liquidity relate to ~~dispense medication, these stores must have a pharmacist onsite~~continuing operations comprised of only our pharmacy technology business for all hours of operation. Many pharmacies have reduced hours of operation based on customer purchasing patterns in order to contain labor cost, which results in further reduced consumer access. Furthermore, retail pharmacy wait times are typically 30 to 60 minutes or more, causing substantial delays for the consumer. During the COVID-19 pandemic, many people are looking to minimize the amount of physical contact that can lead to further disease contraction, especially for those most vulnerable, such as the elderly or those with compromised immune systems. Consequently, some patients are foregoing filling their prescribed medications, leading to declining health, increased healthcare costs and increased morbidity.periods presented.

Components of Operating Results for the ~~Nine~~Three Months Ended ~~September 30, 2022~~March 31, 2023

We have never been profitable and wehave incurred operating losses each year since inception. Our net losses were ~~$36.5~~$17.3 million and ~~$31.2~~$13.0 million for the ~~nine~~three months ended ~~September 30,~~March 31, 2023 and 2022, ~~and 2021,~~ respectively. As of ~~September 30, 2022,~~March 31, 2023, we had an accumulated deficit of ~~$228.6~~$257.0 million. Substantially all of our operating losses resulted from expenses incurred in connection ~~with building out our retail pharmacy services operating footprint and from~~ general and administrative costs associated with our ~~operations.~~operations

We expect to incur ~~significant~~ additional expenses and operating losses ~~for the foreseeable future~~ as we ~~initiate and~~ continue ~~the~~our technology development, ~~deployment~~redeployment of our ~~MedCenter technology~~MedCenters and ~~adding personnel~~right size expenses necessary to operate as a public company with rapidly growing retail pharmacy operations in the United States. In addition, operating as a publicly traded company involves the hiring of additional financial and other personnel, upgrading our financial information systems and incurring costs associated with operating as a public company. We expect that our operating losses will decrease and turn positive as we execute our growth strategies ~~within~~and focus on our ~~operating segments.~~Med Center technologies. If our management

accelerates deployment into new states, operating losses could increase in the near-term, as we grow and scale our ~~operations; we expect operating performance to turn positive once each state reaches sufficient scale in sales volume.~~operations.

As of ~~September 30, 2022,~~March 31, 2023, we had cash and cash equivalents of ~~$27.2~~$18.8 million. We will continue to require additional capital to continue our pharmacy technology development and commercialization activities ~~and build out our pharmacy operations~~ to serve our growing customer base. ~~Accordingly, in November 2020,~~In April and July 2022, and ~~July 2022,~~March 2023, we completed the sale of additional equity through private placement ~~fundings,~~financings, where we raised ~~$83.9 million,~~ $40.0 million and ~~$10.0~~$16.0 million in gross proceeds, respectively. Additionally, in June 2021 we ~~entered into~~added to our liquidity resources through a senior secured term loan ~~and borrowed~~with Silicon Valley Bank, or SBV, of $10.0 million, of which we have repaid $8.0 million. ~~We expect to raise additional capital to continue funding operations.~~As of March 31, 2023, we have an outstanding principal balance of $2.0 million under the term loan. The amount and timing of future funding requirements will depend on many factors, including the pace and results of our growth strategy and capital market conditions. Failure to raise capital as and when needed, on favorable terms or at all, would have a negative impact on our financial condition and our ability to develop product candidates.

Results of Operations for the Three Months Ended March 31, 2023

Pharmacy technology revenue

Hardware revenue

We ~~have two reportable segments: Retail Pharmacy Services~~develop and ~~Pharmacy Technology. These reportable segments are generally defined by how we execute our go-to-market strategy to sell products and services.~~

~~Overview of Retail Pharmacy Services Segment~~

The Retail Pharmacy Services operating segment operates as SpotRx, or the Pharmacy, a full-service retail pharmacy utilizing our automated pharmacy technology, primarily servicing Medicare patients in the United States. In operating SpotRx, we employ the pharmacy team, purchase the medications, and deploy our proprietary technology, the MedCenter, directly into the Medicare-focused clinics. This is an end-to-end turnkey solution.

~~Overview of Pharmacy Technology Segment~~

~~MedAvail Technologies develops and commercializes~~commercialize the MedCenter for direct sale or subscription lease to third-party customers, including some of the world’s largest healthcare providers and systems, as well as large retail chains that provide full retail-pharmacy services using our technology.

~~Results of Operations for the Three Months Ended September 30, 2022~~

~~Revenue – Retail Pharmacy and~~ Hardware ~~and Service~~

~~Retail pharmacy and hardware~~ revenue

~~Retail pharmacy revenue from the Retail Pharmacy Services segment~~ is derived from sales of prescription medications and over-the-counter products to patients. Medications are sold and delivered by various methods including dispensing product directly from the MedCenter, patient pick up at MedAvail’s SpotRx pharmacy locations and home delivery of medications to patient residences. Hardware sales from the pharmacy technology segment are derived from either ~~the~~ sales or subscription leases of the MedCenter to customers.

Service revenue

Service revenue ~~from the Pharmacy Technology Segment~~ is derived from ~~installation~~recurring subscription revenue from software licensing, platform and ~~support~~software hosting, and software and hardware maintenance; and one-time or on demand service revenue from initial installations, and professional services such as training, pharmacy set-up, and consulting services.

Revenue


		Three Months Ended September 30,				2022 vs. 2021					Three Months Ended March 31,				2023 vs. 2022
		2022		2021		Amount Change		% Change			2023		2022		Amount Change		% Change
Pharmacy and hardware revenue:		(in thousands)
Retail pharmacy revenue		$	11,162	$	5,445	$	5,717	105	%
Hardware		—		106		(106)		(100)	%
Subscription		104		108		(4)		(4)	%
Total pharmacy and hardware revenue		11,266		5,659		5,607		99	%
											(in thousands)
Hardware and subscription revenue:										Hardware and subscription revenue:

Hardware revenue										Hardware revenue	$	256	$	56	$	200	357	%
Subscription revenue										Subscription revenue	48		109		(61)		(56)	%
Total hardware and subscription revenue										Total hardware and subscription revenue	304		165		139		84	%
Service revenue:	Service revenue:									Service revenue:

Software	Software	94		51		43		84	%	Software	94		48		46		96	%
Maintenance and support	Maintenance and support	48		44		4		9	%	Maintenance and support	56		32		24		75	%
Installation	Installation	—		11		(11)		(100)	%	Installation	67		6		61		1017	%
Professional services and other	Professional services and other	53		27		26		96	%	Professional services and other	99		14		85		607	%
Total service revenue	Total service revenue	195		133		62		47	%	Total service revenue	316		100		216		216	%
Total revenue	Total revenue	$	11,461	$	5,792	$	5,669	98	%	Total revenue	$	620	$	265	$	355	134	%

During the three months ended ~~September 30, 2022, retail pharmacy~~March 31, 2023, hardware and ~~hardware~~subscription revenue increased by $5.6 million to $11.3 million compared to that of the same period in 2021. The $5.6 million increase was due to a $5.7 million increase from volume growth in prescription revenue at existing sites and additional sites launched primarily in Florida in Q4 2021 and continuing into 2022.

~~During the three months ended September 30, 2022, service revenue increased by~~ $0.1 million to ~~$0.2 million compared to that of the same period in 2021.~~

~~Cost of Products Sold and Services~~

~~Retail pharmacy and hardware cost of products sold~~

~~Cost of products sold consists primarily of prescription medications, other over-the-counter health products; and costs associated with MedCenters sold to third-party customers.~~

~~Service costs~~

~~Service costs consists primarily of costs incurred to install and maintain MedCenters at third-party customer locations.~~

~~Costs of Products and Services~~

Three Months Ended September 30, 2022 vs. 2021
2022 2021 Amount Change % Change
Retail pharmacy and hardware cost of products sold: (in thousands)
Prescription drugs $ 9,313 $ 4,969 $ 4,344 87 %
Shipping 735 396 339 86 %
Hardware 13 129 (116) (90) %
Depreciation 52 45 7 16 %
Total retail pharmacy and hardware cost of products sold 10,113 5,539 4,574 83 %
Service costs:
Professional services 10 16 (6) (38) %
Maintenance and support services 46 46 — — %
Installation services — 5 (5) (100) %
Total service costs 56 67 (11) (16) %
Total cost of products sold and services $ 10,169 $ 5,606 $ 4,563 81 %

During the three months ended September 30, 2022, retail pharmacy and hardware cost of products sold increased $4.6 million to $10.1 million compared to the same period in 2021. The increase was primarily due to costs associated with volume growth in prescription sales at existing

~~sites and additional sites launched primarily in Florida in Q4 2021 and continuing into 2022. Shipping costs, related to our home delivery service via third-party courier, increased~~ $0.3 million compared to the same period in ~~2021.~~2022. The $0.1 million increase was primarily due to a $0.2 million increase MedCenter sales whereby 3 more MedCenters were sold over the same prior year period, partially offset by $0.1 million decrease in subscription lease revenue.

During the three months ended ~~September 30, 2022,~~March 31, 2023, service ~~costs were reasonably consistent with the same period in the prior year.~~

~~Pharmacy Operations~~

Pharmacy operations consist of costs incurred to operate retail pharmacies and our call center. Wages and salaries consist of compensation costs incurred for all pharmacy operations related employees and contractors including bonuses, health plans, severance, and contractor costs. Facility expenses consist of rent and utilities directly associated with our pharmacy operations.

~~Other pharmacy operations expenses consist of supply costs and other costs.~~

Depreciation of property, plant and equipment includes depreciation on MedCenters, IT equipment, leasehold improvements, general plant and equipment, software, office furniture and equipment and vehicles. Amortization of intangible assets consists of amortization of mobile applications and software.

Three Months Ended September 30, 2022 vs. 2021
2022 2021 Amount Change % Change
Pharmacy operations expenses: (in thousands)
Wages and salaries $ 2,375 $ 2,794 $ (419) (15) %
Rent, utilities, and other 569 570 (1) (0) %
Depreciation of property, plant and equipment 242 220 22 10 %
Amortization of intangible assets 1,089 90 999 1110 %
Repairs and maintenance 117 76 41 54 %
Total pharmacy operations expenses $ 4,392 $ 3,750 $ 642 17 %

~~During the three months ended September 30, 2022, pharmacy operations expenses~~revenue increased ~~by $0.6~~$0.2 million to ~~$4.4~~$0.3 million compared to the same period in ~~2021. Amortization of intangible assets has increased~~2022 primarily due to ~~deploying internally developed~~increased services provided as a result of increased MedCenter sales during the three months ended March 31, 2023, compared to the same prior year period..

As a result of the pharmacy services business exit, the Company met the requirements of ASC 205-20, to report the results of the retail pharmacy services business as a discontinued operation. Accordingly, the revenue results for the pharmacy services business have therefore been reclassified as a discontinued operations within these condensed consolidated financial statements.

Pharmacy technology cost of products sold and services

Hardware costs of products

Hardware cost of products sold consists primarily of costs associated with building and customization of MedCenters sold to third-party customers.

Service costs

Service costs consists primarily of installation, integration, relocation, consumable, and maintenance cost of MedCenters at third-party customer locations, as well as related hosting and software costs.

Costs of Products sold and Services


	Three Months Ended March 31,				2023 vs. 2022
	2023		2022		Amount Change		% Change
	(in thousands)
Hardware cost of products sold:


Hardware	$	210	$	56	$	154	275	%
Depreciation	35		25		10		40	%
Total Hardware cost of products sold	245		81		164		202	%
Service costs:
Professional services	14		—		14		—	%
Maintenance and support services	62		47		15		32	%
Installation services	42		3		39		1300	%
Total service costs	118		50		68		136	%
Total cost of products sold and services	$	363	$	131	$	232	177	%

During the three months ended March 31, 2023, hardware cost of products sold increased $164.0 thousand to $0.2 million compared to the same period in ~~our pharmacy operations and decreasing the remaining useful life resulting in an increased amortization of $1.0 million.~~2022. The increase was ~~offset by the decrease in wages and salaries~~primarily due to ~~reduction~~an $154.0 thousand increase in ~~contractor costs.~~hardware costs associated with the increased number of units sold during the three months ended March 31, 2023, as compared to the same prior year period.

During the three months ended March 31, 2023, service costs increased $68.0 thousand primarily due to increased installation cost related to the sale of more MedCenters in the three months ended March 31, 2023, as compared, to the same prior year period.

As a result of the retail pharmacy services business exit, the Company met the requirements of ASC 205-20, to report the results of the retail pharmacy services business as a discontinued operation. Accordingly, the cost of products sold and services results for the retail pharmacy services business have therefore been reclassified as a discontinued operations within these condensed consolidated financial statements.

General and Administrative

General and administrative expenses consist of personnel costs, facility expenses and expenses for outside professional services, including legal, audit and accounting services. Personnel costs consist of salaries, benefits and share-based compensation. Facility expenses consist of rent and other related costs specific to our corporate and technology activities. Corporate insurance, office supplies and technology expenses are also captured within general and administrative expenses. We incurred and expect to incur ~~additional~~ expenses as a result of being a public company, including expenses related to compliance with the rules and regulations of the Securities and Exchange Commission, or SEC, Nasdaq, additional insurance, investor relations and other administrative expenses and professional services.

We have ~~equity incentive plans whereby awards are granted to certain of our employees. The fair value of the~~a stock options and restricted stock units granted by us to our employees is recognized as compensation expense on a straight-line basis over the applicable vesting period. We measure the fair value of the stock options using the Black-Scholes option pricing model as of the grant date. Shares issued upon the exercise of stock options and vesting of restricted stock units are new shares. We estimate forfeitures based on historical experience and expense related to awards is adjusted over the term of the awards to reflect their probability of vesting. All fully vested awards are expensed.

Three Months Ended September 30, 2022 vs. 2021
2022 2021 Amount Change % Change
General and administrative expenses: (in thousands)
Wages and salaries $ 3,098 $ 2,695 $ 403 15 %
Professional services 531 549 (18) (3) %
Share-based compensation 565 367 198 54 %
Insurance 503 462 41 9 %
Software licenses and support 421 305 116 38 %
Rent, utilities, and other 745 555 190 34 %
Office and IT supplies 88 126 (38) (30) %
Travel and other employee expenses 87 184 (97) (53) %
Depreciation of property, plant and equipment 49 77 (28) (36) %
Total general and administrative expenses $ 6,087 $ 5,320 $ 767 14 %

During the three months ended September 30, 2022, general and administrative costs increased approximately by $0.8 million to $6.1 million compared to that of the same period in 2021. This increase was primarily due to hiring additional administrative staff, increased share-based compensation, as well as other investments necessary for our growth as a public company.

~~Selling and Marketing~~

Selling and marketing expenses consist of personnel costs, marketing and advertising costs, and marketing related expenses for outside professional services. Wages and salaries consist of compensation costs incurred for all selling and marketing employees including our in-clinic customer account managers, including bonuses, health plans, and severance.

Three Months Ended September 30, 2022 vs. 2021
2022 2021 Amount Change % Change
Selling and marketing expenses: (in thousands)
Wages and salaries $ 1,960 $ 1,658 $ 302 18 %
Travel and other employee expenses 86 126 (40) (32) %
Marketing 74 110 (36) (33) %
Other selling and marketing expenses 6 15 (9) (60) %
Total selling and marketing expenses $ 2,126 $ 1,909 $ 217 11 %

During the three months ended September 30, 2022, selling and marketing costs increased approximately by $0.2 million to $2.1 million compared to that of the same period in 2021. This increase was primarily due to personnel related costs associated with hiring additional Clinic Account Managers (CAMs), which directly support the staff and patients at the growing number of medical clinics where we are deployed.

~~Research and Development~~

Research and development expenses represent costs incurred to develop and innovate our MedCenter platform technology, including development work on hardware, software and supporting information technology infrastructure. Wages and salaries consist of compensation costs incurred for research and development employees and contractors including bonuses, health plans, severance, and contractor costs.

Three Months Ended September 30, 2022 vs. 2021
2022 2021 Amount Change % Change
Research and development expenses: (in thousands)
Wages and salaries $ 166 $ 165 $ 1 1 %
Other expenses 12 67 (55) (82) %
Total research and development expenses $ 178 $ 232 $ (54) (23) %

~~During the three months ended September 30, 2022, research and development costs decreased by approximately $0.1 million.~~

~~Interest Income and Expense~~

~~Interest expense consists of accrued interest on outstanding debt and is payable monthly.~~

Three Months Ended September 30, 2022 vs. 2021
2022 2021 Amount Change % Change
Interest income: (in thousands)
Interest income $ — $ 7 $ (7) (100) %
Total interest income $ — $ 7 $ (7) (100) %
Interest expense:
Interest expense $ (315) $ (260) $ (55) 21 %
Total interest expense $ (315) $ (260) $ (55) 21 %

During the three months ended September 30, 2022, interest expense increased compared to the same period in 2021 due to the Company entering into a term loan in June 2021. The interest rate on the term loan was 10.25% on September 30, 2022, compared to 7.25% on September 30, 2021. For more detail on outstanding debt and associated maturities, see Note 8 to the unaudited condensed consolidated financial statements presented elsewhere in this Quarterly Report on Form 10-Q.

~~Results of Operations for the Nine Months Ended September 30, 2022~~

~~Revenue – Retail Pharmacy and Hardware and Service~~

~~Retail pharmacy and hardware revenue~~

Retail pharmacy revenue from the Retail Pharmacy Services segment is derived from sales of prescription medications and over-the-counter products to patients. Medications are sold and delivered by various methods including dispensing product directly from the MedCenter, patient pick up at MedAvail’s SpotRx pharmacy locations or home delivery of medications to patient residences. Hardware sales from the pharmacy technology segment are derived from either the sales or subscription of the MedCenter to customers.

~~Service revenue~~

~~Service revenue from the Pharmacy Technology Segment is derived from installation and support services.~~

~~Revenue~~

Nine Months Ended September 30, 2022 vs. 2021
2022 2021 Amount Change % Change
Pharmacy and hardware revenue: (in thousands)
Retail pharmacy revenue $ 30,652 $ 13,357 $ 17,295 129 %
Hardware 236 470 (234) (50) %
Subscription 322 338 (16) (5) %
Total pharmacy and hardware revenue 31,210 14,165 17,045 120 %
Service revenue:
Software 228 125 103 82 %
Maintenance and support 127 115 12 10 %
Installation 77 39 38 97 %
Professional services and other 117 405 (288) (71) %
Total service revenue 549 684 (135) (20) %
Total revenue $ 31,759 $ 14,849 $ 16,910 114 %

During the nine months ended September 30, 2022, retail pharmacy and hardware revenue increased by $17.0 million to $31.2 million compared to that of the same period in 2021. The $17.0 million increase was due to a $17.3 million increase from volume growth in prescription revenue at existing sites and additional sites launched primarily in Florida in Q4 2021 and continuing into 2022, offset by the decrease in hardware revenue from the same period in 2021.

~~During the nine months ended September 30, 2022, service revenue decreased by $0.1 million to $0.5 million compared to the same period in 2021.~~

~~Cost of Products Sold and Services~~

~~Retail pharmacy and hardware cost of products sold~~

~~Cost of products sold consists primarily of prescription medications, other over-the-counter health products; and costs associated with MedCenters sold to third-party customers.~~

~~Service costs~~

~~Service costs consist primarily of costs incurred to install and maintain MedCenters at third-party customer locations.~~

~~Costs of Products and Services~~

Nine Months Ended September 30, 2022 vs. 2021
2022 2021 Amount Change % Change
Retail pharmacy and hardware cost of products sold: (in thousands)
Prescription drugs $ 26,402 $ 12,154 $ 14,248 117 %
Shipping 2,059 976 1,083 111 %
Hardware 245 482 (237) (49) %
Depreciation 121 132 (11) (8) %
Total retail pharmacy and hardware cost of products sold 28,827 13,744 15,083 110 %
Service costs:
Professional services 33 301 (268) (89) %
Maintenance and support services 139 105 34 32 %
Installation services 49 20 29 145 %
Total service costs 221 426 (205) (48) %
Total cost of products sold and services $ 29,048 $ 14,170 $ 14,878 105 %

During the nine months ended September 30, 2022, retail pharmacy and hardware cost of products sold increased by $15.1 million to $28.8 million compared to that of the same period in 2021. The increase was primarily due to costs associated with volume growth in prescription sales at existing sites and additional sites launched primarily in Florida in Q4 2021 and continuing into 2022. Shipping costs, related to our home delivery service via third-party courier, increased by $1.1 million compared to that of the same period in 2021.

~~Pharmacy Operations~~

~~Other pharmacy operations expenses consist of supply cost and other costs.~~

Nine Months Ended September 30, 2022 vs. 2021
2022 2021 Amount Change % Change
Pharmacy operations expenses: (in thousands)
Wages and salaries $ 7,970 $ 7,330 $ 640 9 %
Rent, utilities, and other 1,602 1,102 500 45 %
Depreciation of property, plant and equipment 694 641 53 8 %
Amortization of intangible assets 1,362 187 1,175 628 %
Repairs and maintenance 342 168 174 104 %
Total pharmacy operations expenses $ 11,970 $ 9,428 $ 2,542 27 %

During the nine months ended September 30, 2022, pharmacy operations expenses increased by $2.5 million to $12.0 million compared to that of the same period in 2021. This increase was primarily due to adding our Orlando central pharmacy location in Q4 2021 and continued growth of our other pharmacies. Additionally, volume growth continued to ramp up at existing pharmacy locations, thus increasing pharmacy personnel and supplies, resulting in increased wages, salaries, and operating costs. Amortization of intangible assets has increased as a result of deploying internally developed software in our pharmacy operations and decreasing the remaining useful life resulting in an increased amortization of $1.0 million

~~General and Administrative~~

General and administrative expenses consist of personnel costs, facility expenses and expenses for outside professional services, including legal, audit and accounting services. Personnel costs consist of salaries, benefits and share-based compensation. Facility expenses consist of rent and other related costs specific to our corporate and technology activities. Corporate insurance, office supplies and technology expenses are also captured within general and administrative expenses. We incurred and expect to incur additional expenses as a result of being a public company, including expenses related to compliance with the rules and regulations of the SEC, Nasdaq, additional insurance, investor relations and other administrative expenses and professional services.

~~We have an equity incentive~~ plan whereby awards are granted to certain of our employees. The fair value of the stock options and restricted stock units granted by us to our employees is recognized as compensation expense on a straight-line basis over the applicable vesting period. We measure the fair value of the stock options using the Black-Scholes option pricing model as of the grant date. Shares issued upon the exercise of

stock options and vesting of restricted stock units are new shares. We estimate forfeitures based on historical experience and expense related to awards ~~are~~is adjusted over the term of the awards to reflect their probability of vesting. All fully vested awards are expensed.


		Nine Months Ended September 30,				2022 vs. 2021					Three Months Ended March 31,				2023 vs. 2022
		2022		2021		Amount Change		% Change			2023		2022		Amount Change		% Change
General and administrative expenses:	General and administrative expenses:	(in thousands)								General and administrative expenses:	(in thousands)
Wages and salaries	Wages and salaries	$	9,699	$	8,044	$	1,655	21	%	Wages and salaries	$	2,543	$	2,957	$	(414)	(14)	%
Professional services	Professional services	2,087		2,714		(627)		(23)	%	Professional services	919		591		328		55	%
Share-based compensation	Share-based compensation	1,741		948		793		84	%	Share-based compensation	618		569		49		9	%
Insurance	Insurance	1,509		1,357		152		11	%	Insurance	239		440		(201)		(46)	%
Software licenses and support	Software licenses and support	1,132		785		347		44	%	Software licenses and support	185		13		172		1323	%
Rent, utilities, and other	Rent, utilities, and other	1,944		1,895		49		3	%	Rent, utilities, and other	379		482		(103)		(21)	%

Office and IT supplies	Office and IT supplies	286		270		16		6	%	Office and IT supplies	39		40		(1)		(3)	%
Travel and other employee expenses	Travel and other employee expenses	212		566		(354)		(63)	%	Travel and other employee expenses	13		65		(52)		(80)	%
Depreciation of property, plant and equipment	Depreciation of property, plant and equipment	119		154		(35)		(23)	%	Depreciation of property, plant and equipment	25		33		(8)		(24)	%
Total general and administrative expenses	Total general and administrative expenses	$	18,729	$	16,733	$	1,996	12	%	Total general and administrative expenses	$	4,960	$	5,190	$	(230)	(4)	%

During the ~~nine~~three months ended ~~September 30, 2022,~~March 31, 2023, general and administrative costs ~~increased~~decreased approximately ~~by $2.0~~$0.2 million to ~~$18.7~~$5.0 million compared to ~~that of~~ the same period in 2021. This increase was primarily due to hiring additional administrative staff, increased share-based compensation, as well as other investments necessary for our growth as a public company. Professional services decreased approximately by $0.6 million to $2.1 million compared to that of the same period in 2021.2022. This decrease was primarily due to ~~the~~ reduction in wages and salaries of ~~fees~~$0.4 million resulting from ~~data warehousing, legal~~a reduced headcount and ~~audit costs.~~

lower insurance costs of $0.2 million, partially offset by a $0.3 million increase in professional services costs related to our private placement funding and consultant support services within our finance department due to employee turnover.

Selling and Marketing

Selling and marketing expenses consist of personnel costs, marketing and advertising costs, and marketing related expenses for outside professional services. Wages and salaries consist of compensation costs incurred for all selling and marketing employees including our ~~in-clinic~~in clinic customer account managers, and contractors including bonuses, health plans, and severance.


		Nine Months Ended September 30,				2022 vs. 2021					Three Months Ended March 31,				2023 vs. 2022
		2022		2021		Amount Change		% Change			2023		2022		Amount Change		% Change
Selling and marketing expenses:	Selling and marketing expenses:	(in thousands)								Selling and marketing expenses:	(in thousands)
Wages and salaries	Wages and salaries	$	6,167	$	4,411	$	1,756	40	%	Wages and salaries	$	112	$	59	$	53	90	%
Travel and other employee expenses	Travel and other employee expenses	286		242		44		18	%	Travel and other employee expenses	—		41		(41)		(100)	%
Marketing	Marketing	260		378		(118)		(31)	%	Marketing	20		—		20		100	%
Other selling and marketing expenses		25		25		0		0	%

Total selling and marketing expenses	Total selling and marketing expenses	$	6,738	$	5,056	$	1,682	33	%	Total selling and marketing expenses	$	132	$	100	$	32	32	%

During the ~~nine~~three months ended ~~September 30, 2022,~~March 31, 2023, selling and marketing costs increased approximately ~~by $1.7~~$0.03 million to ~~$6.7~~$0.1 million compared to ~~that of~~ the same period in ~~2021.~~2022. This increase was primarily due to ~~personnel related costs associated with hiring additional Clinic Account Managers (CAMs) which directly support the staff~~a $0.1 million increase in salaries and ~~patients at the growing number of medical clinics where we are deployed.~~wages partially offset by a $0.04 million decrease in travel and other employee expenses.

Research and Development


		Nine Months Ended September 30,				2022 vs. 2021					Three Months Ended March 31,				2023 vs. 2022
		2022		2021		Amount Change		% Change			2023		2022		Amount Change		% Change
Research and development expenses:	Research and development expenses:	(in thousands)								Research and development expenses:	(in thousands)
Wages and salaries	Wages and salaries	$	534	$	498	$	36	7	%	Wages and salaries	$	171	$	191	$	(20)	(10)	%
Other expenses	Other expenses	418		103		315		306	%	Other expenses	5		67		(62)		(93)	%
Total research and development expenses	Total research and development expenses	$	952	$	601	$	351	58	%	Total research and development expenses	$	176	$	258	$	(82)	(32)	%

During the ~~nine~~three months ended ~~September 30, 2022,~~March 31, 2023, research and development costs ~~increased by~~decreased approximately ~~$0.4~~$0.1 million. This ~~increase~~decrease was primarily due to ~~ongoing~~the completion of prior period product improvement ~~activities, including efforts to integrate our MedPlatform® Enterprises Software with the EPIC pharmacy management system for material and subcontractor costs reflected in other expenses.~~activities.

Interest ~~Income and~~ Expense

Interest expense consists of accrued interest on outstanding debt and is payable monthly.


		Nine Months Ended September 30,				2022 vs. 2021					Three Months Ended March 31,				2023 vs. 2022
		2022		2021		Amount Change		% Change			2023		2022		Amount Change		% Change
Interest income:		(in thousands)
Interest income		$	1	$	74	$	(73)	(99)	%
Total interest income		$	1	$	74	$	(73)	(99)	%
											(in thousands)
Interest expense:	Interest expense:									Interest expense:
Interest expense	Interest expense	$	(845)	$	(328)	$	(517)	158	%	Interest expense	$	169	$	251	$	(82)	(33)	%
Total interest expense	Total interest expense	$	(845)	$	(328)	$	(517)	158	%	Total interest expense	$	169	$	251	$	(82)	(33)	%

During the ~~nine~~three months ended ~~September 30, 2022,~~March 31, 2023, interest expense ~~increased~~decreased $0.1 million compared to the same period in ~~2021~~2022, due to a decrease in outstanding debt during the ~~Company entering into a term loan in June 2021. The interest rate on the term loan was 10.25% on September 30, 2022,~~3 months ended March 31, 2023, as compared to ~~7.25% on September 30, 2021. For more detail on~~the same period in the prior year. Total outstanding debt ~~and associated maturities, see Note 8~~principal was $2.0 million as of March 31, 2023, as compared to ~~the unaudited condensed consolidated financial statements presented elsewhere in this Quarterly Report on Form 10-Q.~~

$10.0 million as of March 31, 2022.

Liquidity and Capital Resources

Sources of Liquidity

Since inception through ~~September 30, 2022,~~March 31, 2023, our operations have been financed primarily by net cash proceeds from the sale of stock and warrants from private placements, the sale of redeemable preferred stock and debt. As of ~~September 30, 2022,~~March 31, 2023, we had ~~$27.2~~$18.8 million in cash and cash equivalents and an accumulated deficit of ~~$228.6~~$257.0 million. ~~We added~~

On March 10, 2023, SVB, based in Santa Clara, California, was closed by the California Department of Financial Protection and Innovation, which appointed the FDIC as receiver. On March 10, 2023, the Federal Deposit Insurance Corporation (the “FDIC”) took control of SVB and created the National Bank of Santa Clara to ~~our liquidity resources~~hold the deposits of SVB after SVB was unable to continue their operations. SVB’s deposits are insured by the FDIC in ~~2021 through~~amount up to $250 thousand for any depositor and any deposit in excess of this insured amount could be lost. On March 12, 2023, the U.S. Treasury, Federal Reserve, and FDIC announced that SVB depositors will have access to all deposited funds starting March 13, 2023.

On March 9, 2023, we closed a ~~senior secured term loan facility with Silicon Valley Bank~~private placement, or the ~~Loan Agreement,~~“Offering”, of securities with certain institutional investors pursuant to the terms of a definitive securities purchase agreement. The Offering consists of pre-funded warrants to purchase common stock (the “Pre-Funded Warrants”) issued upon closing at a price of $0.3212 per underlying share and are exercisable into shares of common stock at an exercise price of $0.01 per share, as well as, Series A warrants to purchase common stock an exercise price of $0.385440 per share (the “Series A Warrants”) to be issued following stockholder approval of the Offering. The issuance of the Series A Warrants (including the underlying shares of common stock) and the portion of the Pre-Funded Warrants in excess of 19.99% of the shares of Common Stock outstanding prior to the Offering are subject to approval by the stockholders of MedAvail.

The Pre-Funded Warrant shares are exercisable for an aggregate of up to 49,813,198 shares of common stock, and the Series A Warrants would be exercisable for an aggregate of up to 49,813,198 shares of common stock. Upon close of the transaction MedAvail received gross proceeds from the Offering of approximately $16 million, before deducting offering expenses. The Company intends to use the net proceeds from this offering to fund one-time costs associated with restructuring, repay outstanding debt, and finance MedAvail’s growth initiatives related to its MedCenter technology business.

On February 10, 2022 and March 29, 2023, the Company entered into the First Loan Amendment and Consent, and Letter Agreement, respectively, which provides waivers of any legal action or enforcement of rights and remedies with respect to the specified defaults enumerated therein, on and prior to February 10, 2023 and March 29, 2023. As of the date of this report, we ~~borrowed $10.0 million~~are in ~~aggregate initial term loans.~~ compliance with all covenants under the terms of our Loan Agreement.

In April 2022, we completed a private placement, pursuant to which we received $40.0 million in gross proceeds before deducting placement agent commissions and other offering expenses. An additional $10.0 million in gross proceeds closed on July 1, 2022.

In connection with the private placement, we issued callable warrants in April 2022 and July 2022. The warrant call option is exercisable by us beginning on each of the 12-month and 24-month anniversaries of the warrant issuance dates and subject to the satisfaction of certain pricing conditions relating to the trading of our shares. If the warrants are exercised in full immediately after issuance by the Investors, we would receive additional gross

proceeds of up to $29.4 million. If we exercise our call option immediately after issuance, then we could raise approximately $19.6 million in gross proceeds.

In June, 2021 we added to our liquidity resources through a senior secured term loan facility with SVB, or the Loan Agreement, pursuant to which we borrowed $10.0 million in aggregate initial term loans. In December 2022, and February 2023, the Company made discretionary principal payments to reduce our senior secured term loan by $5.0 million and $3.0 million, respectively. In conjunction with the $3.0 million principal payment an additional $0.4 million was paid related to required final payments. For more detail on outstanding debt and associated maturities, see Part I, Item I,. Note 8 in this report of our unaudited condensed consolidated financial statements of this Quarterly Report on Form 10-Q and Note 13 and Note 21 in our Annual Financial Statements presented in our Annual Report on Form 10-K for the year ended December 31, 2022, which was filed with the SEC, on April 14, 2023.

As of March 31, 2023, we had approximately $9.8 million on deposit with SVB and $9.7 million on deposit with another financial institution. We do not anticipate a material impact on our financial condition, operations or Loan and Security Agreement with SVB. We continue to monitor the circumstances surrounding SVB. As of the date of this filing we have full access to and control over all our cash and, cash equivalents across all financial institutions.

Management is ~~also~~continuously exploring additional sources of financing, the success of which is dependent on market conditions. ~~Management has concluded that the aforementioned conditions, including the ongoing uncertainty related~~In continued efforts to ~~the~~address negative impacts offrom the ~~COVID-19 pandemic~~economy, and the economic uncertainties related to the conflict in Ukraine resulting from the military actions of Russia, including on the global economy, interest rate fluctuations, inflationary pressures and our supply chain, ~~raise~~management is looking to others financial strategies such a stock splits and warrant exercise, should market conditions allow. Given our recent private placement and reduction in operating cost due to the disposition of our retail pharmacy services business, management believes there is no substantial doubt about our ability to continue as a going concern within 12 months from the date of issuance of the financial statements. ~~Our plans to address this uncertainty include raising additional funding, as necessary, through public or private equity or debt financings.~~

~~However, we may not be able to secure additional financing in a timely manner or on favorable terms, if at all.~~

Furthermore, if we issue equity securities to raise additional funds, our existing stockholders may experience dilution, and the new equity securities may have rights, preferences and privileges senior to those of our existing stockholders. Failure to raise capital, however, as and when needed, on favorable terms or at all, would have a negative impact on our financial condition and our ability to develop our product candidates. Our management actively evaluates matters of liquidity and growth capital needs, including evaluating debt and equity as sources of growth capital with a focus on lower overall weighted average cost of capital and favorable financing terms. Our primary uses of liquidity are operating activities, capital expenditures, and lease payments.

Cash Flows

The following table summarizes our cash ~~flows:~~flows for the three months ended March 31, 2023 and 2022:


		Nine Months Ended September 30,				2022 vs. 2021					Three Months Ended March 31,				2022 vs. 2020
(In thousands)	(In thousands)	2022		2021		Amount Change		% Change		(In thousands)	2023		2022		Amount Change		% Change
Cash used in operating activities	Cash used in operating activities	$	(37,283)	$	(28,174)	$	(9,109)	32	%	Cash used in operating activities	$	(5,210)	$	(13,264)	$	8,054	(61)	%
Cash used in investing activities	Cash used in investing activities	(1,897)		(2,269)		372		(16)	%	Cash used in investing activities	(17)		(852)		835		(98)	%
Cash provided by financing activities		46,963		8,722		38,241		438	%
Cash provided by (used in) financing activities										Cash provided by (used in) financing activities	12,579		(23)		12,602		(54791)	%
Net increase (decrease) in cash and cash equivalents, and restricted cash	Net increase (decrease) in cash and cash equivalents, and restricted cash	$	7,783	$	(21,721)	$	29,504	(136)	%	Net increase (decrease) in cash and cash equivalents, and restricted cash	$	7,352	$	(14,139)	$	21,491	(152)	%

Operating Activities

During the ~~nine~~three months ended ~~September 30, 2022,~~March 31, 2023, cash used in operating activities ~~increased by $9.1~~decreased $8.1 million to ~~$37.3~~$5.2 million compared to ~~that of~~ the same period in ~~2021.~~2022. The ~~increase~~decrease in cash used in operating activities was primarily due to ~~an increase~~exiting the retail pharmacy business in ~~inventory, accounts receivable,~~January 2023, with reduced operating ~~expenses from wages and salaries, and costs attributable~~activities during the three months ended March 31, 2023, as compared to the ~~launch and growth of our retail pharmacy operations~~same period in ~~Arizona, California, Michigan, and Florida, and operating as a public company.~~the prior year.

Investing Activities

During the ~~nine~~three months ended ~~September 30, 2022,~~March 31, 2023, cash used in investing activities decreased ~~by $0.4~~$0.8 million to ~~$1.9~~$0.02 million compared to ~~that of~~ the same period in ~~2021.~~2022. The decrease during the three months ended March 31, 2023 was primarily due to aan decrease in investment in property, plant and equipment and intangible software assets ~~associated~~as compared to the same prior year period.

Financing Activities

During the three months ended March 31, 2023, cash provided by financing activities increased $12.6 million to compared to the same period in 2022. The increase is primarily due to the $16.0 million of funds received pursuant the Offering of securities with ~~investments in Retail Pharmacy Services Segment.~~certain institutional investors. This increase of funds was partially offset by a $3.0 million payment on our senior secured term loan with SVB during the three months ended March 31, 2023.

3528

~~Financing Activities~~

Cash Flows Related to Discontinued Operations

~~During~~

As a result of the ~~nine~~retail pharmacy services business exit, the Company met the requirements of ASC 205-20 to report the results of the retail pharmacy services business as a discontinued operation. Accordingly, the cash flows from discontinued operations are as noted below and within these condensed consolidated financial statements.

Cash provided by operating activities by the pharmacy services business totaled $3.5 million and $0.1 million for the three months ended ~~September 30,~~March 31, 2023 and March 31, 2022, ~~cash provided by~~respectively. Cash used in investing activities from the pharmacy services business totaled $0.02 million and $0.35 million for the three months ended March 31, 2023 and March 31, 2022, respectively. Cash used in financing activities ~~increased by $38.2~~from the pharmacy services business totaled $0.03 million ~~to $47.0~~and $0.02 million ~~compared to that~~for the three months ended March 31, 2023 and March 31, 2022, respectively. Depreciation and amortization expense of the ~~same period in 2021.~~ ~~The increase was primarily due to issuance of common shares~~pharmacy services business totaled $0.75 million and ~~warrants through a private placement in April 2022 and July 2022, with no similar activity during~~$0.48 million for the ~~nine~~three months ended ~~September 30, 2021, offset by $10.0 million from debt proceeds during the nine months ended September 30, 2021, with no similar activity in the current period.~~March 31, 2023 and March 31, 2022, respectively.

Critical Accounting Estimates

~~There were no significant changes~~

Our discussion and analysis of our financial condition and results of operations are based upon our consolidated financial statements, which have been prepared in accordance with GAAP. The preparation of our consolidated financial statements and related disclosures requires us to make estimates, assumptions and judgments that affect the reported amounts of assets, liabilities, revenues, costs and expenses and related disclosures. We believe that the estimates, assumptions and judgments involved in the accounting policies described below have the greatest potential impact on our consolidated financial statements and, therefore, we consider these to be our critical accounting estimates. Accordingly, we evaluate our estimates and assumptions on an ongoing basis. Our actual results may differ from these estimates under different assumptions and conditions. Please refer to Note 4 in ~~the nine months ended September 30, 2022, from those previously disclosed~~our consolidated financial statements included in Item 8 of our Annual Report on Form 10-K for information about our significant accounting policies, and Part II, Item 7 of our Annual Report on Form 10-K for the year ended December 31, ~~2021,~~2022, filed with the SEC on April 14, 2023.

Critical estimates in applying the Company’s accounting policies

Derivative Warrant Liabilities

The Pre-Funded Warrants and Series A Warrants do not meet the equity classification requirements under ASC 815 - Derivative and Hedging, specifically the Company did not have a sufficient amount of Common Stock available to be issued to settle the warrants upon grant and through March ~~29, 2022.~~31, 2023, due to the Nasdaq 19.99% cap that limits the Company's ability to issue Common Stock to settle the Series A Warrants and Pre-funded Warrants. Consequently, the Pre-Funded Warrants and Series A Warrants were classified as liabilities and therefore measured at fair value. The Company uses the Black-Scholes pricing model to estimate fair value of these warrants at issuance and at each exercise and period end date. The key assumptions used in the model are the expected future volatility in the price of the Company’s shares, exercise price of the warrants, risk free rates relative to the expected life of the warrants, and the expected life of the warrants. The impact of changes in key assumptions as described see Part I, Item I, Note 12 in this report of our unaudited condensed consolidated financial statements of this Quarterly Report on Form 10-Q.

Recent Accounting Pronouncements

For a discussion of recent accounting pronouncements, see Part II, Item 8, Note 5 of our Annual Report on Form 10-K for the year ended December 31, ~~2021,~~2022, filed with the SEC on ~~March 29, 2022,~~April 14, 2023, and Note 4: "Recent Accounting Pronouncements" in the notes to our unaudited condensed consolidated financial statements included elsewhere in this Quarterly Report Form 10-Q.

3629

Item 3. Quantitative and Qualitative Disclosures About Market Risk

As a “smaller reporting company”, we are not required to provide the information required by this Item.

Item 4. Controls and Procedures

Disclosure Controls and Procedures

Our management, with the participation of our Chief Executive Officer and Chief Financial Officer, has evaluated the effectiveness of our disclosure controls and procedures, ~~(as~~as such term is defined in Rules 13a-15(e) and 15d-15(e) under the Securities Exchange Act of 1934, as amended, or the Exchange ~~Act),~~Act, as of March 31, 2023, the end of the period covered by this ~~report.~~ Quarterly Report on Form 10-Q. Based on such evaluation, our Chief Executive Officer and Chief Financial Officer have concluded that as of ~~the end of such period,~~March 31, 2023, our disclosure controls and procedures were not effective because of the material weakness in our internal control over financial reporting described below.

In connection with the preparation of our Annual Report on Form 10-K for the year ended December 31, 2022, our management identified the following material weakness in our internal control over financial reporting that caused management to conclude that, as of December 31, 2022, our disclosure controls and procedures were not effective:

•Our initial supporting documentation for certain technical accounting matters did not adequately address the appropriate accounting guidance, which was indicative of a lack of controls relating to our financial reporting process, including the evaluation and analysis of accounting treatment for complex, non-standard transactions.

The material weakness identified in connection with the preparation of our Annual Report on Form 10-K had not been fully remediated as of March 31, 2023.Notwithstanding the material weakness in our internal control over financial reporting as of March 31, 2023, management has concluded that the condensed consolidated financial statements included in this report present fairly, in all material respects, our financial position, results of operations and cash flows for the periods presented in conformity with accounting principles generally accepted in the United States.

Remediation of Material Weakness

We recognize the importance of the control environment. Consequently, we are ~~effective.~~designing and implementing remediation measures to address the material weakness and enhance our internal control over financial reporting. Management is taking the following actions, which we believe will remediate the material weakness:

•We are designing and implementing additional controls relating to (i) the preparation of initial supporting documentation for certain technical accounting matters in order to adequately address the appropriate accounting guidance, including the evaluation and analysis of accounting treatment for complex, non-standard transactions, and (ii) the engagement of external consultants to provide support and assistance in our evaluation of complex, non-standard transactions.

Changes in Internal Control Over Financial Reporting

There ~~have not~~has been ~~any changes~~no change in our internal control over financial reporting (as such term is defined in Rules 13a-15(f) and 15d-15(f) under the Exchange Act) during the quarter ended ~~September 30, 2022~~March 31, 2023 that has materially affected, or is reasonably likely to materially affect, our internal control over financial reporting.The material weakness associated with our financial reporting discussed above did not result in the initiation of remediation activities until after March 31, 2023.

Limitations on Effectiveness of Controls and Procedures

In designing and evaluating the disclosure controls and procedures, management recognizes that any controls and procedures, no matter how well designed and operated, can provide only reasonable assurance of achieving the desired control objectives. In addition, the design of disclosure controls and procedures must reflect the fact that there are resource constraints and that management is required to apply judgment in evaluating the benefits of possible controls and procedures relative to their costs.

3730

PART II

Item 1. Legal Proceedings

The information set forth under the heading “Legal” in Note 10, Commitments and Contingencies, in Part I, Item 1 of this Quarterly Report on Form 10-Q is incorporated herein by reference.

Item 1A. Risk Factors

Except as set forth below, there have been no material changes ~~from~~to the risk factors disclosed in Part I, Item 1A. “Risk Factors” of our Annual Report on Form 10-K for the year ended December 31, ~~2021,~~2022, or the ~~“2021~~2022 Annual ~~Report",~~Report, filed with the Securities and Exchange Commission on ~~March 29, 2022.~~April 14, 2023. The risk factors described in our ~~2021~~2022 Annual Report, as well as other information set forth in this Quarterly Report on Form 10-Q, could materially adversely affect our business, financial condition, results of operations and prospects, and should be carefully considered. The risks and uncertainties that we face, however, are not limited to those described in the ~~2021~~2022 Annual Report. Additional risks and uncertainties not presently known to us or that we currently believe to be immaterial may also adversely affect our business and the trading price of our ~~securities, particularly in light of the fast-changing nature of the COVID-19 pandemic, containment measures and the related impacts to economic and operating conditions.~~securities.

Our share price does not meet the minimum bid price for continued listing on Nasdaq. Our ability to continue operations or to publicly or privately sell equity securities and the liquidity of our common stock could be adversely affected if we do not regain compliance with the minimum bid price requirement and we are delisted from Nasdaq.

WeOn October 31, 2022, we received a deficiency letter from Nasdaq notifying us that for the ~~last~~prior 30 consecutive business days the bid price for our common stock had closed below the minimum $1.00 per share requirement for continued inclusion on the Nasdaq Capital Market pursuant to Nasdaq Listing Rule 5550(a)(2) (the “Bid Price Rule”). In accordance with Nasdaq Listing Rule 5810(c)(3)(A), we ~~have~~had 180 calendar days starting on October 31, 2022, or until May 1, 2023, to regain compliance with the Bid Price Rule. On May 2, 2023, Nasdaq informed us of its decision to extend the period for us to regain compliance with the Bid Price Rule by an additional 180 calendar days, or until October 30, 2023. If, at any time before ~~May 1,~~October 30, 2023, the bid price for our common stock closes at $1.00 or more for a minimum of 10 consecutive business days, we will regain compliance with the Bid Price Rule, unless the Nasdaq staff exercises its discretion to extend this 10-day period pursuant to Nasdaq listing rules. We have not regained compliance with Nasdaq Listing Rules as of the filing date of this Quarterly Report on Form 10-Q.

If we do not regain compliance with Nasdaq Listing Rule 5550(a)(2) by May 1, 2023, we may be eligible for additional time to comply. To qualify, we will be required to meet certain continued listing requirements for market value of publicly held shares and all other initial listing standards for Nasdaq. If we meet these requirements, Nasdaq may grant us an additional 180 calendar daysWe intend to regain compliance with the Bid Price Rule ~~and we may provide written notice to Nasdaq of our intention to cure the deficiency during the additional compliance period. One method to regain compliance in such circumstances would be to implement~~by implementing a reverse stock split ~~but there~~of our common stock at a ratio in the range of not less than 1-for-30 and no greater than 1-for-80, with such ratio to be determined in the discretion of our board of directors or a duly authorized committee thereof. Our stockholders will vote on a proposal to approve the reverse stock split at our annual meeting of stockholders scheduled for June 14, 2023. There is no guarantee that athe reverse stock split ~~would~~will be approved by ~~the~~our stockholders or that a reverse stock split ~~would~~will allow us to regain compliance with the Bid Price Rule, and ~~such an action~~a reverse stock split could result in an adverse effect on or negatively impact the price of our common stock.

If we do not regain compliance with the Bid Price Rule and are not eligible for or are not granted an additional compliance period, our common stock may be delisted. There can be no assurance that, if we receive a delisting notice and appeal the delisting determination by the Nasdaq staff, such appeal would be successful. There can be no assurance that we will maintain compliance with the other requirements for listing our common stock on Nasdaq.

Delisting could adversely affect our ability to raise additional capital through the public or private sale of equity securities, ~~which would~~and could significantly affect the ability of investors to trade our securities, ~~and~~which would negatively affect the value and liquidity of our common stock.

We and our stockholders could be materially adversely impacted if our common stock is delisted from Nasdaq. In particular:

•we may lose the confidence of our current or prospective third-party providers and collaboration partners, which could jeopardize our ability to enter into supply, manufacturing, licensing, and collaboration agreements and continue our business as currently conducted;

•we could be in a material breach under agreements we have with third parties, such as the Loan and Security Agreement between us and Silicon Valley Bank;

•the price of our common stock will likely decrease;

•stockholders may be unable to sell or purchase our common stock when they wish to do so;

•the potential loss of confidence by employees;

•we may lose the interest of institutional investors in our common stock;

•we may have fewer business development opportunities;

•we may lose the interest of institutional investors in our common stock;

•we may have fewer business development opportunities;

•we may lose media and analyst coverage;

•our common stock could be considered a “penny stock,”’ which would likely limit the level of trading activity in the secondary market for our common stock; and

•we would likely lose the active trading market for our common stock, as it may only be traded on one of the ~~over-the-counter~~over-the counter markets, if at all.

As of the date of this Quarterly Report on Form 10-Q, except for the risk factor described above with respect to the deficiency in connection with the Bid Price Rule, there have been no material changes to the risk factors disclosed in the 2021 Annual Report filed with the Securities and Exchange Commission on March 29, 2022. We may disclose additional changes to such factors or disclose additional factors from time to time in our future filings with the Securities and Exchange Commission.

Item 2. Unregistered Sales of Equity Securities and Use of Proceeds

On July 1, 2022, the Company sold and issued 9,411,765 Shares and Warrants to purchase 4,705,881 Warrant Shares in a private placement, which was previously disclosed by the Company on its Current Report on Form 8-K filed July 1, 2022.None.

Item 3. Defaults Upon Senior Securities

None.

Item 4. Mine Safety Disclosures

None.

Item 5. Other Information

None.

3932

Item 6. Exhibits

Incorporated by Reference
Exhibit Number Description Form Exhibit Filing Date
3.1
Amended and Restated Certificate of Incorporation of MedAvail Holdings, Inc.
8-K 3.1 June 16, 2022
3.2
Amended and Restated Bylaws of MedAvail Holdings, Inc.
8-K 3.2 November 18, 2020
4.1
Form of Common Stock Purchase Warrant issued by MedAvail, Inc.
8-K 4.1 November 18, 2020
4.2
Amended and Restated Investors’ Rights Agreement by and among the Registrant, MedAvail, Inc., and certain stockholders, dated October 9, 2020
S-4/A 4.9 October 9, 2020
4.3
Form of Common Stock Purchase Warrant issued by the Registrant to H.C. Wainwright & Co., LLC or its affiliates
8-K 4.3 November 18, 2020
4.4
Securities Purchase Agreement, dated as of March 30, 2022
8-K 10.1 April 4, 2022
4.5
Registration Rights Agreement, dated as of March 30, 2022
8-K 10.2 April 4, 2022
4.6
Form of Warrant
8-K 10.3 April 4, 2022
4.7
Sales Agreement dated as of August 12, 2022.
S-3 1.2 August 12, 2022
10.1#
MedAvail Holdings, Inc. 2022 Inducement Equity Incentive Plan and related forms of stock option and restricted stock unit agreements.
8-K 10.1 April 8, 2022
16.1
Letter to the Securities and Exchange Commission from PricewaterhouseCoopers LLP, dated July 11, 2022
8-K 16.1 July 11, 2022
31.1*
Certification of Chief Executive Officer pursuant to Exchange Act Rules 13a-14(a) and 15d-14(a), as adopted pursuant to Section 302 of the Sarbanes-Oxley Act of 2002
31.2*
Certification of Principal Financial Officer pursuant to Exchange Act Rules 13a-14(a) and 15d-14(a), as adopted pursuant to Section 302 of the Sarbanes-Oxley Act of 2002
32.1**
Certifications of Chief Executive Officer and Principal Financial Officer pursuant to 18 U.S.C. Section 1350, as adopted pursuant to Section 906 of the Sarbanes-Oxley Act of 2002
101* Inline XBRL Document Set for the condensed consolidated financial statements and accompanying notes in Part I, Item 1, “Financial Statements” of this Quarterly Report on Form 10-Q
104* Inline XBRL for the cover page of this Quarterly on Form 10-Q, included in the Exhibit 101 Inline XBRL Document Set

Incorporated by Reference

Exhibit Number

Description

Form

Exhibit

Filing Date

3.1

Amended and Restated Certificate of Incorporation of MedAvail Holdings, Inc.

8-K

3.1

June 16, 2022

3.2

Amended and Restated Bylaws of MedAvail Holdings, Inc.

8-K

3.2

November 18, 2020

4.1

Securities Purchase Agreement, dated as of March 9, 2023

8-K

10.1

March 14, 2023

4.2

Registration Rights Agreement, dated as of March 9, 2023

8-K

10.2

March 14, 2023

4.3

Form of Pre-Funded Warrant to Purchase Common Stock

8-K

10.3

March 14, 2023

4.4

Form of Series A Warrant to Purchase Common Stock

8-K

10.4

March 14, 2023

4.5

Warrant to Purchase Stock dated February 10, 2023 issued to Silicon Valley Bank

8-K

10.2

February 16, 2023

4.6

Warrant to Purchase Stock dated February 10, 2023 issued to SVB Innovation Credit Fund VIII, L.P.

8-K

10.3

February 16, 2023

10.1#

Separation Agreement and Release by and between MedAvail Holdings, Inc. and Steven Hess

8-K

10.1

February 10, 2023

10.2#

Separation Agreement and Release by and between MedAvail Holdings, Inc. and Matt Broome

8-K

10.2

February 10, 2023

10.3

First Amendment, Consent and Default Waiver to Loan and Security Agreement dated February 10, 2023, by and among MedAvail Holdings, Inc., MedAvail Pharmacy, Inc., MedAvail, Inc., MedAvail Technologies (US) Inc., MedAvail Technologies, Inc., Silicon Valley Bank, and SVB Innovation Credit Fund VIII, L.P.

8-K

10.1

February 16, 2023

10.4

Letter Agreement dated March 29, 2023

8-K

10.1

April 3, 2023

31.1*

Certification of Chief Executive Officer pursuant to Exchange Act Rules 13a-14(a) and 15d-14(a), as adopted pursuant to Section 302 of the Sarbanes-Oxley Act of 2002

31.2*

Certification of Principal Financial Officer pursuant to Exchange Act Rules 13a-14(a) and 15d-14(a), as adopted pursuant to Section 302 of the Sarbanes-Oxley Act of 2002

32.1**

Certifications of Chief Executive Officer and Principal Financial Officer pursuant to 18 U.S.C. Section 1350, as adopted pursuant to Section 906 of the Sarbanes-Oxley Act of 2002

101*

Inline XBRL Document Set for the condensed consolidated financial statements and accompanying notes in Part I, Item 1, “Financial Statements” of this Quarterly Report on Form 10-Q

104*

Inline XBRL for the cover page of this Quarterly on Form 10-Q, included in the Exhibit 101 Inline XBRL Document Set

~~§ Portions of this exhibit have been redacted in compliance with Regulation S-K Item 601(a)(6) and Item 601(b)(10).~~

# Indicates a management contract or compensatory plan.

* Filed herewith.

** Furnished herewith.

4033

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its

behalf by the undersigned thereunto duly authorized.


	MEDAVAIL HOLDINGS, INC.

Date: ~~November 10, 2022~~May 18, 2023	By:	/s/ Mark Doerr
		Mark Doerr
		President and Chief Executive Officer ~~and~~ (Principal Executive ~~Officer~~Officer)

	By:	/s/ Ramona Seabaugh
		Ramona Seabaugh
		Chief Financial Officer ~~and~~ (Principal Financial ~~Officer~~and Accounting Officer)

4134


	Common Shares			Preferred Shares (1)			Warrants		Additional Paid-in-Capital		Accumulated Deficit		Accumulated Other Comprehensive Loss		Total Stockholders' Equity
	Shares	Amount		Shares	Amount
Balance at June 30, 2022	70,609,972	$	71	—	$	—	$	8,876	$	247,598	$	(216,830)	$	(6,928)	$	32,787
Net loss	—	—		—	—		—		—		(11,806)		—		(11,806)
Issuance of common shares	9,411,765	9		—	—		—		9,751		—		—		9,760
Issuance of warrants	—	—		—	—		2,272		(2,272)		—		—		—

Shares issued for vested restricted stock units	23,959	—		—	—		—		—		—		—		—

Share-based compensation	—	—		—	—		—		565		—		—		565
Balance at September 30, 2022	80,045,696	$	80	—	$	—	$	11,148	$	255,642	$	(228,636)	$	(6,928)	$	31,306

Balance at December 31, 2021	32,902,048	$	33	—	—		$	1,373	$	216,685	$	(192,090)	$	(6,928)	$	19,073
Net loss	—	—		—	—		—		—		(36,546)		—		(36,546)
Issuance of common shares	47,058,820	47		—	—		—		46,914		—		—		46,961
Issuance of warrants	—	—		—	—		9,775		(9,775)		—		—		—
Shares issued for vested restricted stock units	30,833	—		—	—		—		—		—		—		—

Issuance of common shares under employee stock purchase plan	53,995	—		—	—		—		77		—		—		77
Share-based compensation	—	—		—	—		—		1,741		—		—		1,741
Balance at September 30, 2022	80,045,696	$	80	—	$	—	$	11,148	$	255,642	$	(228,636)	$	(6,928)	$	31,306






Balance at June 30, 2021	32,583,734	$	33	—	$	—	$	1,485	$	215,700	$	(168,191)	$	(6,928)	$	42,099
Net loss	—	—		—	—		—		—		(11,273)		—		(11,273)


Exercise of warrants	171,191	—		—	—		(112)		139		—		—		27
Share-based compensation	—	—		—	—		—		365		—		—		365

Balance at September 30, 2021	32,754,925	$	33	—	$	—	$	1,373	$	216,204	$	(179,464)	$	(6,928)	$	31,218


Balance at December 31, 2020	31,816,020	32		—	—		2,614		213,624		(148,275)		(6,928)		61,067
Net loss	—	—		—	—		—		—		(31,189)		—		(31,189)
Exercise of options	144,101	—		—	—		—		241		—		—		241
Exercise of warrants	794,804	1		—	—		(1,241)		1,391		—		—		151
Share-based compensation	—	—		—	—		—		948		—		—		948


Balance at September 30, 2021	32,754,925	$	33	—	$	—	$	1,373	$	216,204	$	(179,464)	$	(6,928)	$	31,218


	Three Months Ended September 30, 2021
	Current presentation		As previously reported		Change
Pharmacy operations	$	3,750	$	2,395	$	1,355
General and administrative	5,320		6,805		(1,485)
Selling and marketing	1,909		1,779		130
	$	10,979	$	10,979	$	—


	Nine Months Ended September 30, 2021
	Current presentation		As previously reported		Change
Pharmacy operations	$	9,428	$	6,619	$	2,809
General and administrative	16,733		19,941		(3,208)
Selling and marketing	5,056		4,657		399
	$	31,217	$	31,217	$	—


			Fair Value Hierarchy
(in thousands)	September 30, 2022		Level 1		Level 2		Level 3
Assets:
Cash and cash equivalents	$	27,196	$	27,196	$	—	$	—
Restricted cash	676		676		—		—
Total assets	$	27,872	$	27,872	$	—	$	—


			Fair Value Hierarchy
(in thousands)	December 31, 2021		Level 1		Level 2		Level 3
Assets:
Cash and cash equivalents	$	19,689	$	19,689	$	—	$	—
Restricted cash	400		400		—		—
Total assets	$	20,089	$	20,089	$	—	$	—


September 30, 2022
Issue Date	Reason for issuance	Term (years)	Exercise Price (USD)
April 4, 2022	Private Placement	5	$	1.25
July 1, 2022	Private Placement	5	$	1.25


	Retail Pharmacy Services		Pharmacy Technology		Total
Three Months Ended September 30, 2022
Revenue:
Pharmacy and hardware revenue:
Retail pharmacy revenue	$	11,162	$	—	$	11,162
Hardware	—		—		—
Subscription	—		104		104
Total pharmacy and hardware revenue	11,162		104		11,266
Service revenue:

Software	—		94		94
Maintenance and support	—		48		48
Installation	—		—		—
Professional services and other	—		53		53
Total service revenue	—		195		195
Total revenue	11,162		299		11,461
Cost of products sold and services	10,047		122		10,169
Segment gross profit	$	1,115	$	177	1,292
Operating expense:
Pharmacy operations					4,392
General and administrative					6,087
Selling and marketing					2,126
Research and development					178
Total operating expense					12,783
Operating loss					$	(11,491)


	Retail Pharmacy Services		Pharmacy Technology		Corporate		Total
September 30, 2022
Assets	$	15,939	$	7,953	$	25,959	$	49,851
Liabilities	$	5,841	$	2,689	$	10,015	$	18,545
December 31, 2021
Assets	$	13,641	$	5,222	$	19,280	$	38,143
Liabilities	$	5,618	$	3,567	$	9,885	$	19,070